



LJMU Research Online

Islam, Y, Leach, AG, Smith, J, Pluchino, S, Coxon, CR, Sivakumaran, M, Downing, J, Fatokun, AA, Teixidò, M and Ehtezazi, T

Peptide based drug delivery systems to the brain

<http://researchonline.ljmu.ac.uk/id/eprint/12936/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Islam, Y, Leach, AG, Smith, J, Pluchino, S, Coxon, CR, Sivakumaran, M, Downing, J, Fatokun, AA, Teixidò, M and Ehtezazi, T (2020) Peptide based drug delivery systems to the brain. Nano Express. ISSN 2632-959X

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

ACCEPTED MANUSCRIPT • OPEN ACCESS

Peptide based drug delivery systems to the brain

To cite this article before publication: Yamir Islam *et al* 2020 *Nano Ex.* in press <https://doi.org/10.1088/2632-959X/ab9008>

Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is © 2020 The Author(s). Published by IOP Publishing Ltd.

As the Version of Record of this article is going to be / has been published on a gold open access basis under a CC BY 3.0 licence, this Accepted Manuscript is available for reuse under a CC BY 3.0 licence immediately.

Everyone is permitted to use all or part of the original content in this article, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by/3.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required. All third party content is fully copyright protected and is not published on a gold open access basis under a CC BY licence, unless that is specifically stated in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

Peptide based drug delivery systems to the Brain.

Yamir Islam¹, Andrew G. Leach^{1,2}, Jayden Smith⁶, Stefano Pluchino⁴,

Christopher R. Coxon^{1,3}, Muttuswamy Sivakumaran⁵, James Downing¹,

Amos A. Fatokun,¹ Meritxell Teixidò⁷, Touraj Ehtezazi^{1*}

¹School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK.

²Division of Pharmacy and Optometry, The University of Manchester, Stopford Building Oxford Road, Manchester M13 9PT, UK.

³School of Engineering and Physical Sciences, Heriot-Watt University, William Perkin Building, Edinburgh, EH14 4AS, UK.

⁴Department of Clinical Neurosciences, Clifford Allbutt Building - Cambridge Biosciences Campus and NIHR Biomedical Research Centre, University of Cambridge, Hills Road, CB2 0HA Cambridge, UK.

⁵Department of Haematology, Peterborough City Hospital, Edith Cavell Campus, Bretton Gate Peterborough, PE3 9GZ, Peterborough, UK.

⁶Cambridge Innovation Technologies Consulting (CITC) Limited, St. John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK.

⁷Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldri Reixac 10, Barcelona 08028, Spain.

* Corresponding author

Abstract

With estimated worldwide cost over \$1 trillion just for dementia, diseases of the central nervous system pose a major problem to health and healthcare systems, with significant socio-economic implications for sufferers and society at large. In the last two decades, numerous strategies and technologies have been developed and adapted to achieve drug penetration into the brain, evolving alongside our understanding of the physiological barriers between the brain and surrounding tissues. The blood brain barrier (BBB) has been known as the major barrier for drug delivery to the brain. Both invasive and minimally-invasive approaches have been investigated extensively, with the minimally-invasive approaches to drug delivery being more suitable. Peptide based brain targeting has been explored extensively in the last two decades. In this review paper, we focused on self-assembled peptides, shuttle peptides and nanoparticles drug delivery systems decorated/conjugated with peptides for brain penetration.

Key words:

Blood brain barrier, drug delivery, brain, nanoparticles, nanotechnology, shuttle peptides.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abbreviations

α -Syn	α -synuclein
ABCB1	ATP-binding cassette sub-family B member 1 (ABCB1)
AC	Astrocyte
AChR	Acetylcholine receptor
AD	Alzheimer’s disease
AF6	LL1-fused gene from chromosome 6 protein
AFM	Atomic force microscopy
AMT	Adsorptive-mediated transport
ANG	Angiopep
ApoB	Apolipoprotein B
ApoE	Apolipoprotein E
AuNP	Gold nanoparticle
ASNP	Alginate-stearic acid nanoparticles
B6	CGHKAKGPRK peptide
BBB	Blood-brain barrier
BCSFB	Blood-cerebrospinal fluid barrier
BSA	Bovine serum albumin
CNT	Carbon nanotubes
CMC	Critical micelle concentration
CNS	Central nervous system
CSF	Cerebrospinal fluid
DLS	Dynamic light scattering
EAE	Experimental autoimmune encephalomyelitis
ECs	Endothelial cells
FBS	foetal bovine serum
FITC	Fluorescein isothiocyanate
g7	7-amino acid glycoprotein, GFtGPLS (O- β -d-Glucoseglucose)CONH ₂
GE11	CYHWYGYTPQNVI peptide
GSH	Glutathione

HD	Huntington's disease
HIFU	High-intensity focused ultrasound
HuHtt	Human huntingtin exon 1
IFN- α	Interferon- α
IFN- γ	Interferon gamma
i.v.	Intravenous
Lamp2b	Lysosome-associated membrane protein 2b
LDLR	Low-density lipoprotein receptor
LRP-1	lipoprotein receptor-related protein 1
MCAO	Middle cerebral artery occlusion
miniAp-4	H-DapKAPETALD-NH ₂ peptide
MMP	Matrix metalloproteinase
MND	Motor neurone disease
MOR	Opioid receptor mu
MS	Multiple sclerosis
MSC	Mesenchymal stem/stromal cell
MWCNT	Multi wall carbon nanotubes
nAChR	Nicotinic acetylcholine receptor
ND	Neurodegenerative Disease
NP	Nanoparticle
NIR	Near infrared
NVUs	Neurovascular Units
NW	Nanowire
PAH	Poly allylamine hydrochloride
PD	Parkinson's Disease
PEG	Polyethylene glycol
PepH3	AGILKRW peptide
PLA	Poly(lactic acid)
PMNP	Polymeric nanoparticles
pSiNPs	Porous silica nanoparticles

1		
2		
3	RES	Reticuloendothelial system
4		
5	ROS	Reactive oxygen species
6		
7	RVG	Rabies virus glycoprotein
8		
9	RVG-29	YTIWMPENPRPGTPCDIFTNSRGKRASNG
10		
11	SWCNT	Single wall carbon nanotubes
12		
13	SE	Status epilepticus
14		
15	SEM	Scanning electron microscopy
16		
17	siRNA	Small interfering RNA
18		
19	SNALP	Stable nucleic acid lipid particle
20		
21	SPION	Superparamagnetic iron oxide nanoparticle
22		
23	t-MCAO	transient middle cerebral artery occlusion
24		
25	TAT	Trans-activating transcriptional activator
26		
27	TEM	Transmission electron microscopy
28		
29	Tf	Transferrin
30		
31	TfR	Transferrin receptor
32		
33	TJ	Tight junction
34		
35	TNF- α	Tumor necrosis factor- α
36		
37	WHO	World Health Organisation
38		
39	ZO	Zonula occludens (a.k.a. tight junction protein)
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1. Introduction

The central nervous system (CNS) comprises the brain and the spinal cord. Any injury or damage to the CNS affects its normal functioning and may lead to permanent disability in many cases, due to a largely limited ability for neural tissue regeneration in humans [1, 2]. The broad term “Neurodegenerative Diseases” (NDs) covers a range of pathologies, principally affecting neurons in the brain and causing significant neuronal dysfunction, neuronal death and neuronal loss. NDs once established are irreversible and sapping conditions resulting in progressive degeneration of neuronal cells [3]. The signs and symptoms are diverse in range, depending on the affected part of the brain. The cause of an ND is often unknown but can involve a complex convergence of multiple molecular mechanisms; and disease progression is usually unpredictable. NDs include a number of conditions: Alzheimer’s disease (AD) and other forms of primary dementias, Multiple Sclerosis (MS) and other forms of chronic inflammatory neurological disease, Parkinson’s disease (PD), Motor Neurone Disease (MND), Huntington’s disease (HD) and ataxias [4]. The World Health Organisation (WHO) reported that NDs affect around 0.1 billion individuals (24 million individuals suffer from AD and other dementias)[5] all over the world, and the incidence is on the rise as average life expectancy is increasing. Around 850,000 people in the UK are affected by dementia, costing the healthcare system over £26 billion a year [6]. In the US nearly 100 million people are affected by NDs costing around \$724 billion in 2014 [7]. It is estimated that the cost of AD would be over 1 trillion dollars worldwide [8]; and the estimated number of people with dementia will reach 131.5 million by 2050 [9] in the absence of effective therapies. Just in Europe, the annual cost of neurological disease reaches 800 billion Euros per year, with a majority attributed to direct costs [10].

The brain is one of the most vital and sensitive organs in the body, which, to perform its functions in an appropriate way, needs nutrients and gases [11]. Due to its pivotal role and functions, it is protected in a number of ways, including by the skull, the outer skin, three layers of meninges and the blood-brain barrier (BBB) [12]. The BBB is a layer of endothelial cells (ECs) associated with pericytes (PCs) and astrocytes (ACs) and acts as a separator of the blood from parenchymal cells, thus preventing penetration of drugs into the CNS. It therefore protects the brain from overexposure to substances such as potassium, glycine and glutamate, which, in high levels such as found in pathological conditions, are neurotoxic [13, 14].

Despite many advances in drug delivery systems that target the brain, it is still a challenging area. The failure of therapies administered via an intravenous (i.v.) or an oral route is often due to their inability to cross/penetrate the brain parenchyma. The use of peptides for drug delivery to the brain has been extensively explored in the last decade. Self-assembled peptides, shuttle peptides and peptide-decorated nanoparticles have been reported to effectively deliver drugs in the brain. This review covers peptide based drug delivery systems for the brain and future prospects.

2. Blood-Brain Barrier

Figure 1 is the schematic representation of healthy and diseased BBB. Numerous gateways have been reported to provide access the brain; the most significant are through blood stream or by getting access to the cerebrospinal fluid (CSF) circulation. Penetration of any molecules administered via the parenteral route is controlled by the BBB, the blood–cerebrospinal fluid barrier (BCSFB), arachnoid barrier and circumventricular organ barrier. However, drug molecules up taken by the brain are flushed back towards the blood through the return of the CSF to the blood or transporters on the BBB [15]. The BBB acts as a guard filter that prevents the uptake of large-molecules and more than 98% of pharmaceuticals [12, 16] and small-

molecule drugs [17]. Small molecules that are lipid soluble, electrically neutral and weak bases may be able to diffuse passively across the BBB.




Figure 1: BBB composition and pathological conditions. (A) In normal states, the BBB comprises vascular endothelial cells connected with TJs and the PCs layer. A basement membrane linked with AC end-feet surrounds the endothelium. (B) Increased permeability of the BBB in pathological conditions results from high matrix metalloproteinase (MMP) activity and increased reactive oxygen species (ROS) and nitric oxide (NO) levels. Cytokines and chemokines are released and then activate microglia/macrophages, leading to basement membrane degradation, TJs disruption and an inflammatory response.

Thus, the BBB, with its extensive blood capillary network, is considered the most important barrier that controls a molecule's access to the brain parenchyma. Neurovascular units (NVUs) comprising endothelial cells, extracellular base membrane, adjoining pericytes, astrocytes, and microglia (although not a structural component of the BBB, are often included in the NVU as they influence barrier function in response to injury and disease [18] are integral parts of the BBB supporting system [19]. NVUs collect signals from the adjacent cells and generate functional responses that are crucial for appropriate CNS function [20, 21]. Both tight intracellular junctions (i.e. zona occludens, characteristic of the BBB) and the absence of fenestrations limit the permeability of drug molecules [22].

Various transport routes have been reported by which solutes and drug molecules can cross the BBB,[23, 24] as shown in [Figure 2](#). Diffusion of substances across the BBB can be generally categorised into paracellular (namely the transfer of nutrients/drugs across an epithelium by passing through the intercellular space between the cells) and transcellular (namely the movements of solutes through a cell). In order to cross the BBB by passive diffusion, various parameters play pivotal roles. Molecular mass is an important factor and the ideal molecular weight reported to be suitable for passive diffusion is <400 Da [25]. A value of between 5.0 and 6.0 for the log of the octanol-water partition coefficient ($\log P_{o/w}$), a measure of lipophilicity, is suitable for passive diffusion [26].




Figure 2. Transport routes across the BBB. Solute molecules follow from “a” to “f” pathways and the route “g” involves monocytes, macrophages and NPs (NPs).

Compounds that are lipophilic, neutral or uncharged at pH 7.4 and have less than 8 hydrogen bonding groups are more suitable to cross the BBB [27]. In another study, reported by Partridge in 2012, [28] it was found that small drug molecules can cross the BBB if their molecular mass is less than 400 and they have the ability to form 8-10 hydrogen bonds. Unfortunately, it has been reported that more than 98% of drugs for the CNS are unable to cross the BBB adequately to attain the minimum therapeutic concentration [12]. Several invasive and non-invasive approaches have been anticipated to evade the BBB and enhance drug delivery to the CNS.

3. Novel Shuttle peptides

Shuttle peptides facilitate the influx of a diverse range of small molecule cargoes across the BBB. The concept of shuttle peptides for BBB was coined by William M Partridge in the mid-1980s [29]. Small synthetic peptide shuttles (comprising natural amino acids) have been reported to cross the BBB. For example, the short rabies virus glycoprotein (RVG), RVG-29 (YTIWMPENPRPGTPCDIFTNSRGKRASNG), binds exclusively to the nicotinic acetylcholine (nAChR) receptor found on neuronal cells and on the endothelial cell lining of the BBB, making it possible for peptide carriers to penetrate [30]. Javed *et al.* (2016) used C2-9r (H₂N-CDIFTNSRGKRAGGGGrrrrrrrr, where r is D-arginine) to deliver siRNA for suppressing the α -synuclein (α -Syn) gene, implicated in the development of PD. CDIFTNSRGKRA is a shorter version of RVG, linked with four extra glycine acting as a spacer and positively charged arginine (R), which at the end of the C-terminus bind with negatively-charged siRNA. It was reported that this delivery system (peptide-based) not only crosses the BBB, but also stabilizes the siRNA that suppresses the α -Syn protein, thus mitigating PD-like symptoms [31]. Although this delivery system has been derived from the rabies virus, it was reported to be non-toxic to neuronal cells.

Venom-derived, peptide-based shuttles have been reported to cross the BBB and to be able to deliver drugs to the desired site. Oller-Salvia *et al.* (2016) have demonstrated that miniAp-4 (H-DapKAPETALD-NH₂) derived from Apamin (a neurological toxin from bee venom) is able to cross the BBB and can deliver gold nanoparticles (NPs), showing proof of concept for drug delivery [32]. PepH3 (AGILKRW) has shown greater penetration upon i.v. administration in CD1 mice and bio-distribution was measured in mice sacrificed 5 min and 1 h after administration. Furthermore, its clearance and excretion is relatively fast, making it a good candidate for a shuttle carrier [33]. Spontaneous internalisation of nanowires (NW), linked with a cell penetrating peptide: the trans-activating transcriptional activator (TAT) from human immunodeficiency virus 1, has also been reported [34]. Two other shuttle peptides PWVPSWMPPRHT and GPWVPSWMPPRHT (composed of D-amino acids) have been found to cross the BBB and are able to transport drug molecules or diagnostic substances into the CNS. These peptides have been reported to be biocompatible and non-toxic (as they were made up of amino acids) [35]. In recent decades, a number of BBB shuttle peptides with improved efficiency have been reported (Table 1). Apolipoprotein (Apo) derivative peptides have been shown to cross the BBB (in *in vitro* and *in vivo* experiments) [36, 37]. Whilst numerous studies have demonstrated that Apolipoprotein B

(ApoB) (SSVIDALQYKLEGTTTRLTRKRGLKLATALSLSNKFVEGS) and Apolipoprotein E (ApoE) (LRKLRKRL)₂ analogues are able to cross the BBB [38, 39, 40]. Gao *et al.* (2012) reported the use PEG-(poly(ϵ -caprolactone)) NPs (prepared by emulsion solvent evaporation) for brain drug delivery, and contained docetaxel, a widely used drug in the treatment of several malignancies including brain tumours. They successfully conjugated a phage displayed TGN (Table 1) peptide and an AS1411 aptamer, which specifically targets the ligands on the BBB and cancer cells respectively. *In vitro* experiments showed excellent permeability across the BBB along with suitable endothelial monolayer targeting. *In vivo* imaging showed that

unmodified NPs hardly distributed in the brain while AsNPs (AS11411 conjugated NPs) accumulated slightly in the brain. However, the accumulation of TGN conjugated NPs in the brain significantly increased and the brain distribution achieved the highest intensity at 12 h [41]. GRN1005 a peptide-drug conjugate (taxane paclitaxel and angiopep-2 (ANG=TFFYGGSRGKRNNFKTEEY)) that interacts with lipoprotein receptor-related protein 1 (LRP1) has shown excellent permeability across the BBB. Phase I and II clinical trials suggested that GRN1005 was able to cross the BBB and limit tumour growth [42, 43]. Similarly, Li et al. (2016) used a combination of two peptides (ANG and TAT) conjugated with paclitaxel to deliver the drug across the BBB [44]. Zou et al. (2019) used a 16 lysine (K16) residue-linked low-density lipoprotein receptor-related protein (LDLR)-binding amino acid segment of apolipoprotein E (K16APoE) to deliver a therapeutic peptide (HAYED) into an AD mouse model brain leading to reduced the necrosis [45]. Numerous shuttle peptides have been investigated for drug delivery to the brain but there is still a need to find magical combination. In another study, Sonoda *et al.* (2018) formulated a BBB penetrant protein conjugate (JR-141), comprising an anti-human transferrin receptor (hTfR) antibody and human iduronate-2-sulfatase (hIDS) to treat mucopolysaccharidosis II (MPS II, caused by accumulation of glycosaminoglycans) [46]. Upon i.v. administration, JR-141 was detected in the brain but hIDS alone failed to penetrate into the brain. In addition, ostensibly therapeutic outcomes were observed, with a lower accumulation of glycosaminoglycans measured in brain and peripheral tissues [46]. Self-assembled peptide nanoligand derived from phage display library was used to down regulate the BACE1 without toxicity and inflammation [47].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1. A list of shuttle peptides that can target the BBB.

Peptide	Typical Sequence	Origin	Transport Mechanism	Ref
g7	GFtGPLS (O-β-d-glucose)CONH ₂	Enkephalin analogues/ opioid	RMT	[48, 49, 50, 51]
Apamin	H-CNCKAPETALCARRCQQH-NH ₂	Venom neurotoxin	Unknown	[32]
MiniAp-4	[Dap]KAPETALD	Venom neurotoxin	Unknown	[32]
Regulon polypeptides	PTVIHGKREVTLHL	Neurotropic endogenous Protein	LDLR	[52]
RAP	ELKHFEAKIEKHNHYQKQLE	Neurotropic endogenous Protein	LDLR	[52]
Angiopep-2	TFFYGGSRGKRNNFKTEEY	Neurotropic endogenous Protein	LRP1	[53, 54]
TAT (47-57)	GGGGYGRKKRRQRRR	HIV Protein	CD4 + T lymphocytes	[55]
PhPro	[Phenyl-Proline] ₄	Chiral library design	Passive transport (paracellular and transcellular)	[56]
RI-OR2-TAT	Ac-rGffvlkGrrrrqrkkkGy-NH ₂	HIV Protein and Amyloid beta	Aβ peptide binding	[57]
SynB1	RGGRLSYSRRRFSTSTGR	Protegrins	AMT	[58]
Pep 22	Ac-[cMPRLRGC]c-NH ₂	Phage display (receptor)	LDLR	[59]
Leptin 30	YQQVLTSLPSQNVLQIANDLENLRDLLHLLC	Leptin	RMT	[60]

TGN	TGNYKALHPHNG	Phage display	Unknown	[61, 62]
CNG-QSH	(d-CGNHPLAKYNGT) (d-QSHYRHISPAQVC)	Phage display	Unknown/A β peptide binding	[63]
LNP	KKRTLKNDKRC	the nucleolar translocation signal sequence of the LIM Kinase 2 protein	Caveolae-mediated endocytosis and macropinocytosis	[64]
ApoE (157-167)	(LRKLRKLLR) ₂	Apolipoprotein E	LRP1	[38, 39, 65]
ApoB	SSVIDALQYKLEGTTTLTRKRGLKLATALSLSNKFVEGS	Apolipoprotein B	LRP2	[40]
RVG-29	YTIWMPENPRPGTPCDIFTNSRGKRASNG	Rabies Virus Glycoprotein	nAChR	[30]
G23	HLNILSTLWKYRC	Phage display	GM1 and GT1b	[66, 67]
T7	HAIYPRH	Phage display	hTfR	[68, 69, 70, 71]
THR	THRPPMWSPVWP	Phage display	hTfR	[35, 72,
THRre	pwvpswmprrht (retro-enantio version of THR)	Phage display	hTfR	73, 74]
THRre_2f	(pwvpswmprrht) ₂ KKGK(CF)G	Branched - Phage display	hTfR	[75]
DKP	Phe(p-NH-Dhp)-L-N-Me[Cha]/ [2Na]	Unknown	Passive diffusion	[76]

GSH-PEG	GSH[PEG]	Endogenous tripeptide	Glutathione	[77, 78, 79]
CDX	D-[FKESWREARGTRIERG]	Structure-guided design	nAchR	[80, 81]
CRT	CRTIGPSVC	Phage display	TfR	[82]
T7 - #2077	RLSSVDSDLGC	Phage display	RMT	[83]
CAQK	CAQK	Phage display	Proteoglycan complex	[84]

Datta et al. (2000) used a receptor binding domain peptide derived from human apolipoprotein E (hApoE), LRKLRKRLLR [hApoE (141-150)] as a vehicle to cross the BBB. They fused hApoE (141-150) with 18A (DWLKAFYDKVAEKLKEAF) [Ac-He18a-NH₂], a high affinity lipid-associated peptide to assess the uptake and degradation of low-density lipoprotein (LDL) in murine embryonic fibroblast (MEF1). In addition, four analogues were prepared, of which, Ac-LRRLRRRLLR-18A-NH₂ [Ac-hE(R)18A-NH₂] and Ac-LRKMRKRLMR-18A-NH₂ (Ac-mE18A-NH₂) have an extended hydrophobic moiety, including the receptor binding region. Control peptides were Ac-LRLLRKLR-18A-NH₂ [Ac-hE(Sc)18A-NH₂], which has amino acid residues of the ApoE to disrupt the hydrophobic face, and Ac-RRRRRRRRRR-18A-NH₂ (Ac-R1018A-NH₂), which has only positively charged arginine (R) as the receptor binding domain. Increased internalisation of LDL was observed by 3-, 5- and 7-fold by Ac-mE18A-NH₂, Ac-hE18A-NH₂, and Ac-hE(R)18A-NH₂, respectively, whereas the control peptides had no significant biological activity as illustrated in Figure 3 [38]. Wang et al. (2013) used a receptor binding peptide of ApoE (residues 159-167 [monomer: LAVYQAGAR], but the peptide had 18 amino acids, 2×monomer) fused to IDUA (a lysosomal enzyme, α -L-iduronidase) [IDUAe1] to deliver across the BBB by targeting the LRP1, for the treatment of mucopolysaccharidosis (MPS) type I [39]. Zhang et al. (2018) used BBB shuttle peptides to enhance the brain transduction of AAV8 after systemic administration. THR (THRPPMWSPVWP-NH₂), a shuttle peptide that binds specifically to TfR1 was used to promote the internalization and transduction of AAV8 in a dose dependent manner [85].




Figure 3. Schematic presentation of high affinity lipid peptide linked with poly-arginine and ApoE. Peptide conjugated with poly-arginine served as control and no permeation was observed, while conjugated ApoE showed improved internalization into cells.

4. Novel Nanotechnology for brain drug delivery

NPs are carriers composed of natural (e.g. lipidic) or synthetic (e.g. polymeric) materials ranging from 1-500 nm in size. NPs are able to encapsulate, adsorb, or conjugate drugs or diagnostics and release the payload at a specific rate in the human body [86]. The physicochemical properties of NPs such as size, surface charge (zeta potential), morphology and composition are important factors deciding the fate of NPs, such as passage across the BBB, biological activity, release profile and biocompatibility [87]. A list of NPs used for brain drug delivery are summarised in [Table 2](#).

4.1. Polymeric NPs (PMNPs)

Polymeric NPs (PMNPs) are most extensively studied for the purpose of drug delivery. These NPs can not only deliver small drug molecules but can also be used for the delivery of genes and proteins [88]. PMNPs can have good penetration through cell membranes, serum stability, and can be easily manufactured. Furthermore, the surface of NPs can be modified for various medical applications. For brain drug delivery, PMNPs are made up of proteins, amino acids, polysaccharides and polyesters. Different mechanisms can be adapted by the PMNPs to cross the BBB. They can cross the BBB either by transcytosis through endothelial cells, mucoadhesion, or by disturbing the TJ in the brain capillaries [89]. On the other hand, PMNPs can be identified upon i.v. injection by the reticuloendothelial system (RES), leading to wide distribution to liver, spleen and bone marrow, resulting in elimination or very short half-lives [90]. Tf and poly-L-arginine (cell penetrating peptide) linked with 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) liposomes were developed for brain delivery of imaging agents and DNA [91]. B6 (CGHKAKGPRK), a TfR-specific peptide, and GE11 (CYHWYGYTPQNVI), a peptide specific for endothelial growth factor receptor

(EGFR) overexpressed on cancer cells, were linked with poly(amido)amine-PEG (PAMAM-PEG) based dendriplexes for siRNA delivery [92].

PLGA-NPs modified with 7-amino acid glycopeptide (g7) have been shown to deliver small drug molecules across the BBB in rodents. Furthermore, g7-NPs successfully crossed the BBB with model drug (fluorescein isothiocyanate (FITC)-albumin). Injection in wild-type and knockout mice clearly showed penetration into the brain [93]. Luo et al. (2017) developed high-intensity focused ultrasound (HIFU) responsive angiopep-2-decorated poly(lactic-co-glycolic acid) (PLGA) hybrid NPs able to transport doxorubicin/perfluorooctyl bromide (ANP-D/P). Decorated-NPs showed 17-fold increased accumulation in glioblastoma and 13.4 fold higher than unmodified NPs. Significant amount (47%) of drug released within two minutes after HIFU irradiation, causing apoptosis of tumour cells [94]. Methoxypolyethylene glycol (MPEG) and methoxypoly(ethylene glycol)-*b*-polycaprolactone (PCL) NPs, conjugated with angiopep-2 (CTFFYGGSRGKRNNFKTKRY) peptide with encapsulation efficiency of more than 95% showed higher in vivo accumulation in the brain [95].

Di Mauro et al. (2018) developed novel biodegradable block co-polymeric NPs, functionalized with two different peptides AGBBB015F (CGGKTFFYGGSRGKRNNFKTEEY) and Regulon (HKKWQFNSPFVPRADEPARKGKVHIPFLDNITCRVPMAREPTVIHGKREVTLHLHP DH). These peptide functionalized NPs showed higher brain permeability than non-functionalized in U-87 MG cell line [96]. K16ApoE decorated PLGA-NPs have shown better accumulation in the cerebral vasculature. These NPs showed higher uptake into brain and provided better MRI contrast for diagnostic purpose [97].

4.2. Metallic NPs

Metallic NPs for brain delivery have been under investigation due to their serum stability and long half-life. Ghorbani *et al.* (2018) reported the use of gold-iron nanocomposites encapsulated with curcumin-lipoic acid, a pH-sensitive delivery system for the brain. GSH is used as targeting ligand, leading to 2-fold increases in cellular uptake [98]. Nosrati *et al.* (2019) reported the use for glutathione (GSH) decorated iron NPs (GSHIONPs) for brain drug delivery. IONPs@Asp-PTX-PEG-GSH are stable, non-toxic and enhance MRI contrast for diagnostic purpose [99].

In a comparative study conducted by Wang *et al.* (2019) reported the peptide functionalized polyethylene glycol and maleic anhydride-coated superparamagnetic iron oxide nanoparticles (Mal-SPIONs) showed better diffusion to the thalamus, frontal cortex and temporal lobe than bovine serum albumin (BSA) conjugated NPs [100]. In another study, Albertini *et al.* (2019) used AUNPs decorated with RGD like peptides (GRGDG-NH₂, GRGDS) for drug delivery to brain tumour. Two hours after injection, the concentrations of NPs were 1.5 and 5 fold higher than undecorated NPs and PEGylated NPs [101]. TAT-conjugated gold NPs have been employed for brain drug delivery. The cellular uptake of AuNPs-TAT was 7.4% compared to 0.03% of AuNPs-PEG [102]. Chlorotoxin (CTX), a glioma specific peptide conjugated with polyethylenimine-entrapped gold nanoparticles (Au PENPs) showed excellent penetration into brain [103]. Ivask *et al.* (2018) evaluated the uptake of iron oxide NPs conjugated with biomimetic phosphorylcholine brushes in an *in vitro* BBB model system. They reported that after 24 h, 78% of the formulation crossed the BBB via adsorption mediated transport (AMT) [104]. This ability of iron oxide NPs has provided the opportunity of delivering therapeutic peptides to the brain by conjugating the peptide to the surface of iron-oxide NPs (5 nm diameter) [105]. Tf-conjugated magnetic dextran-spermine NPs (DS-NPs) have also demonstrated excellent penetration across the BBB [106].

Kang *et al.* (2016) reported a single-step procedure to simultaneously load porous silicon NPs with high concentrations of siRNA and protecting them by formation of Ca_2SiO_4 at the surface of NPs (pSiNPs). These core-shell NPs had the size of 180 ± 20 nm. Then pSiNPs were surface functionalised with RVG peptide (cell targeting ligand) and a cell penetrating peptide (myr-GWTLNSAGYLLGKINLKALAALAKKIL(GGCC), a myristoylated transportan) to deliver the siRNA across the BBB. Addition of these peptides increased the size of pSiNPs to 220 nm. The pSiNPs were administered intravenously to mice with brain injury, and a significant amounts of siRNA were accumulated at the site of injury [107]. Similarly, Lee *et al.* (2017) reported the use of rabies virus-mimetic silica-coated gold nanorods to treat brain gliomas. The nanorods were prepared by converting spherical gold NPs to gold nanorods. Then coating the gold nanorods with SiO_2 . This was to adjust the size of the nanorods to the size of rabies virus as much as possible. This was followed by coating the resulting Au- SiO_2 nanorods by PEG and RVG-29. The nanorods (RVG-PEG-Au@ SiO_2) had the length of 117.7 ± 7.3 nm and width of 50.3 ± 3.1 nm. The RVG-PEG-Au@ SiO_2 nanorods were administered intravenously to orthotopic glioma-bearing mice, which *in vivo* fluorescence imaging indicated the accumulation of RVG-PEG-Au@ SiO_2 nanorods in the mouse brains. The mice were subjected to photothermal therapy using near infrared (NIR) laser. The temperature changes (up to 60°C) caused by the laser therapy (localized surface plasmon resonance) of gold nanorods resulted in irreversible damages to or death of tumor cells. Tumor volumes in mice treated with RVG-PEG-AuNRs@ SiO_2 nanorods and applying NIR laser were considerably smaller than those of mice treated with PEG-AuNRs@ SiO_2 nanorods or control saline (124.8 ± 147.5 , 1067.4 ± 295.4 , and 2323.2 ± 436.3 mm^3 , respectively) at 7 d after the treatment. Even, the tumors of two mice treated with RVG-PEG-AuNRs@ SiO_2 nanorods nearly vanished. This therapy caused slight skin damage by 808 nm laser irradiation, which was healed after 13 days [108]. This study indicates that even the EPR of the brain tumors was not sufficient to

allow accumulation of PEG-AuNRs@SiO₂ nanorods in the tumors and use of RVG-29 cell targeting peptide was necessary to achieve desired therapeutic outcomes. In addition, the size of RVG-PEG-AuNRs@SiO₂ nanorods could be part of the successful application of these NPs.

Numerous factors control the systemic circulation, cell penetration and BBB passage of NPs. Particle size is one of the important factors controlling the access of NPs across the BBB. Studies conducted in animal models of AD, PD and stroke have used NPs of 50-100 nm [109, 110, 111, 112, 113, 114]. Several techniques, such as dynamic light scattering (DLS), atomic force microscopy (AFM), TEM and scanning electron microscopy (SEM) are used to characterise NPs [115]. Several factors control the particle size, such as the polymers used, drug loading, drug/polymer ratio and hydrophilic/lipophilic ratio. Previous studies have reported an increase in particle size after drug loading [116, 117]. On the other hand, Lopalco *et al.* (2015) have reported no changes in the size of NPs made up of PLGA, PLGA-d- α -tocopheryl polyethylene glycol 1000 succinate (TGPS) and Resomer RGPd5055 pre- and post-loading of drugs (oxcarbazepine and coumarin-6) [118].

4.3. Exosomes

Exosomes are comprised of natural lipid bilayers with an abundance of adhesive proteins that readily interact with cellular membranes. These are small extracellular nanovesicles secreted by numerous cell [119, 120]. Naturally-occurring extracellular vesicles such as exosomes traffic endogenous small molecules, proteins and nucleic acids between cells,[121, 122] and they have shown considerable promise for the delivery of exogenous drugs or biological therapeutics,[123, 124, 125, 126] including to the brain [127, 128]. Exosomes have several advantages over synthetic NPs in that their biocompatibility confers upon them an inherent non-immunogenicity and long circulation times, however surface-functionalisation (e.g. for targeted delivery) and synthetic analogues of ‘natural’ exosomes have also proven to

be successful therapeutic strategies [129, 130, 131]. Drugs delivered by means of an exosomal vector often show enhanced efficacy and fewer adverse effects. Enhancing and exploiting the innate drug-delivery capabilities of exosomes make for a highly attractive therapeutic approach.

Alvarez-Erviti *et al.* (2011) used exosomes (obtained from self-derived dendritic cells) decorated to express Lysosome-associated membrane protein 2b (Lamp2b) and fused with neuron-specific RVG peptide to deliver siRNA into mouse brains [132]. They also compared the immune response of siRNA-RVG exosomes and siRNA-RVG-9R *in vivo* by measuring the interleukin (IL)-6, interferon gamma-induced protein (IP)-10, tumor necrosis factor (TNF)- α and interferon (IFN)- α serum levels. They found non-substantial changes in all cytokines compared to siRNA-RVG-9R [132]. Although, IFN- α and IP-10 increased in average for mice injected with siRNA-RVG exosomes compared to control mice [132].

Curcumin-loaded exosomes tagged with cyclo(Arg-Gly-Asp-D-Tyr-Lys) peptide [c(RGDyK)] were used to target the lesion region of the ischemic brain in a transient middle cerebral artery occlusion (tMCAO) mouse model [133]. Alvarez-Erviti *et al.* (2011) used RVG decorated exosomes to deliver siRNA to the mouse brain [132]. Long *et al.* (2017) used A-1 exosomes (derived from human bone marrow mesenchymal stem/stromal cells (MSCs)) for the rectification of pilocarpine-induced status epilepticus (SE) [134]. Exo-JSI124 exosomes derived from EL-4 cells (a mouse lymphoma cell line) were used to deliver an encapsulated anti-inflammatory drug in experimental autoimmune encephalomyelitis (EAE) mice via an intranasal route, modulating inflammation [135]. Exosomes derived from dendritic cell cultures treated with interferon- γ were found to increase myelination in rats upon intranasal administration, possibly by delivery of miR-219 [136]. Exosomes loaded with superparamagnetic iron oxide NPs (SPIONs) and curcumin and conjugated with neuroleptin-1-targeted peptide (RGERPRR) crossed the BBB and were used for imaging and treatment of

glioma [137]. Iraci *et al.* (2017) revealed the unexpected ability of stem cell exosomes to harbour and deliver functional enzymes (e.g. Asparaginase-like 1) extracellularly, thus behaving as fully independent small metabolic units with exciting therapeutic implications [138].

Cooper *et al.* (2014) described the use of exosomes derived from murine bone marrow dendritic cells to block the aggregation of α -Syn, a pathological process implicated in PD progression. siRNA-loaded exosomes decorated with RVG (targeting ligand) effectively reduced the α -Syn aggregation in normal mice and transgenic mice expressing the human phosphorylation-mimic S129D α -Syn [139]. Dopamine-loaded exosomes derived from the blood of mice were used to deliver drugs across the BBB with lower systemic toxicity compared to i.v. administration of naked dopamine [140]. As an alternative approach, Haney *et al.* (2015) circumvented the BBB, using intranasal delivery to successfully administer the catalase-loaded macrophage-derived exosomes to the brain of mice with a model of PD, resulting in significant neuroprotective effects [119]. Conversely, a potential role of exosomes in diagnosing neurodegenerative conditions was highlighted by Gui *et al.* (2015) who developed a microRNA-profiling strategy for the early detection of PD. They used exosomes isolated from the CSF of PD and AD patients, reporting sixteen miRNAs upregulated and 11 miRNAs under regulated in PD [141].

Liu *et al.* (2015) successfully deployed exosomes expressing RVG on the surface loaded with opioid receptor mu (MOR) siRNA into the brain for the treatment of morphine addiction [142]. Wu *et al.* (2018) also used RVG decorated exosomes for brain drug delivery. They encapsulated siRNA targeting human huntingtin exon 1 (HuHtt) transcript. HuHtt-siRNA loaded RVG-exosomes were then administered intravenously to normal mice and BACHD and N171-82Q transgenic (Huntington's Disease-model) mice at 10 mg/kg every two days for 2

weeks. siRNA-loaded RVG exosomes significantly reduced HuHtt mRNA and protein levels up to 46% and 54%, respectively, in transgenic animals [143].

4.4. Liposomes for brain drug delivery

Liposomes are self-assembled NPs made up of phospholipid bilayer membrane. Phospholipids are heterogeneous molecules containing phosphate residues, polar head groups, and non-polar alkyl chains [144] that self-assemble (according to the fluid mosaic model) into biological membranes. Liposomes for brain drug delivery have been studied extensively in the last two decades.

Pulford et al. (2010) formulated liposomes (178 ± 20 nm) containing cationic lipid octadecenolyoxy[ethyl-2-heptadecenyl-3 hydroxyethyl] imidazolinium chloride to deliver siRNA into the brain of mice following i.v. injection. The cationic liposome-siRNA-peptide (RVG-9r) penetrates the BBB, with the peptide moiety binding to nAChRs [145]. Bender et al. (2016) used two liposomal systems for the delivery of prion protein siRNA to the brain of mice following i.v. injection. One of the liposome formulations was cationic liposomes containing 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), which formed a complex with siRNA and RVG peptide. The other liposomal system contained DOTAP or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) to encapsulate the siRNA. Both systems decreased the prion protein expression of neurons in the CNS [146]. Grinberg et al. (2005) reported novel cationic amphiphilic compounds synthesised from vernonia oil. The quaternary methyl ester derivative of methyl vernolate self-assembled into vesicles (in the presence of cholesterol 1:1) with the size of 50-200 nm in diameter [147]. Vesicles made from the quaternary vernonia oil derivative (triple-headed amphiphile) were found to be efficient in transfection of cDNA encoding for GFP into cultured COS-7 cells [147]. These vesicles were employed to deliver analgesic

peptides (kyotorphin or leu-enkephalin) to the brain of male ICR mice following i.v. injection [148].

Moreover, Conceicao *et al.* (2016) reported that the RVG-9r peptide decorated liposomes (also referred as stable nucleic acid lipid particles [SNALPs]) were able to cross the BBB and deliver siRNA, which can target mutant ataxin-3 in the brain of Machado-Joseph disease mouse models. These SNALPs offered high encapsulation of siRNA, optimum particle size and almost no toxicity. *In vivo* experiments showed the ability of SNALPs to accumulate in the brain and silence the mutant ataxin-3 upon i.v. injection as shown in Figure 4 [149].




Figure 4. *In vivo* images showing the uptake of the RVG-9r decorated SNALPs in mice (C57 BL/6 ataxin-3 [Q69]-transgenic) after i.v. injection reproduced from [149] after permission (NI: non-injected animal, RV-MAT-9r: non-targeted liposomes, RVG-9r: targeted-liposomes).

Table 2. A summary of formulations (NPs) targeting the BBB.

Formulation/Polymer	Drug	Disease	Method used for NP preparation	Mechanism for BBB crossing	Key Findings	Ref
g7-PLGA-NPs (NPs of less than 300 nm)	FITC-albumin	MPS I and MPS II	Double emulsion technique	RMT	The C57BL/6 Idua knockout and C57BL/6 Ids knockout mice were used. High MW molecule delivery across the BBB achieved	[93]
Functionalized solid lipid NPs with apolipoprotein E, (SLN-DSPE-ApoE) (Average size was less than 200 nm with zeta potential of -10-15 mV)	Resveratrol	Neuroprotective	High shear homogenization	LDLR	<i>In vitro</i> cytotoxicity evaluation via MTT and LDH using hCMEC/D3 cell line showed that SLNs affected neither	[150]

					the metabolic activity of the cells nor the membrane integrity at concentrations less than 1500 µg/mL. hCMEC/D3 monolayers in transwell devices showed SLN-DSPE-ApoE, permeabilities 1.5-fold higher than for non-functionalized SLNs	
Bovine Serum Albumin NPs with LMWP cell penetrating peptide (LMWP-albumin)	PTX and 4-HPR	Brain cancer	Self-assembly	Brain penetration mainly by EPR, but also through SPARC and gp60	FACS showed <i>in vitro</i> cellular uptake of the NPs.	[151]

<p>[LMWP: CVSRRRRRRRGRRRR] (Particle size less than 200 nm,)</p>				<p>albumin binding proteins overexpressed in glioma tissues</p>	<p>bEnd.3 cell line showed BBB penetration of the NPs U87 cells showed cytotoxicity of NPs. The NPs were administered by i.v. injection to orthotopic glioma (Luc- U87) mouse model (bearing intracranial tumor). The mice received the NPs (LMWP-modified bovine serum albumin (BSA) NPs containing PTX and 4-HPR)</p>
--	--	--	--	---	---

					showed the longest survival time	
PEG–PLA-penetratin (RQIKIWFQNRRMKWKK) (Particle size 100 nm, zeta potential -4.42 mV)	Coumarin-6	CNS disorders	Emulsion/solvent evaporation technique	AMT/RMT	MDCK-MDR cell model	[152]
					showed enhanced accumulation via both lipid raft-mediated endocytosis and direct translocation. <i>In vivo</i> administration showed significant brain uptake with less deposition in non-target tissues	
Angiopep conjugated with poly(ethylene glycol)-co-poly(ε-caprolactone): ANG-PEG– poly(ε-caprolactone)	Paclitaxel	Glioblastoma multiforme	Sonication	LDLR	U87 MG glioma cells	[153]
					indicated the ANG-PEG-poly(ε-caprolactone) NPs	

(Particle size was less than 100 nm with zeta potential of 3.28 ± 0.75 mV)					uptake via LDLR (Angiopep-2 and Aprotinin significantly reduced the cellular uptake of the NPs). Real time fluorescence imaging showed accumulation of ANG-NPs in the brain of intracranial U87 MG glioma tumor-bearing nude mice after i.v. injection.	
TAT-poly(ethylene glycol) (PEG)-b-cholesterol: TAT-PEG-b-Chol	Ciprofloxacin	Encephalitis	Self-assembly	AMT	Enhanced <i>in vitro</i> cellular (ACBRI 376) uptake. NPs crossed the	[154]

(Particle size less than 200 nm)					BBB and located around the cell nucleus of neurons (SD adult rats) following i.v. injection	
RVG-29-PEG-PLGA/DTX-NPs (Particle size was around 110 nm)	Docetaxel	Gliomas	Nanoprecipitation	nAchR	<i>In vitro</i> bEnd3 cells showed permeability across the BBB. RVG-29-PEG-PLGA/DTX-NPs had a stronger inhibitory effect on C6 cell proliferation than free DTX. <i>In vivo</i> experiments confirmed selective accumulation of NPs in intracranial	[155]

					glioma tissues following i.v. injection.	
PEG-Poly(ϵ-caprolactone)-CH₂R₄H₂C/Stearate-CH₂R₄H₂C (CH₂R₄H₂C: CHHRRRRHHC peptide) (Particle size was in the range of 50-100 nm with zeta potential of 15-20 mV)	Dextran (as model drug)	CNS disorders	Self-assembly	Olfactory nerve channels	Hydrophobic carrier is more suitable for the delivery of drug in forebrain, while hydrophilic carrier is suitable for hindbrain (brainstem).	[156]
g7- PLGA-Np (Particle size was in the range of 155±26 nm with zeta potential of -15±5.6 mV)	Loperamide	CNS disorders	Nanoprecipitation	AMT	Long term <i>in vitro</i> release over 192 hours and 20% in 2 hours. <i>In vivo</i> experiments showed excellent bio-distribution in brain.	[157, 158]

mPEG-PLGA-RVG (Particle size was in the range of 168.8 ± 1.9 nm with zeta potential of -27.40 ± 0.71 mV)	Deferoxamine	PD	Double emulsion technique	nAchR	<i>In vivo</i> administration reduced the oxidative stress and iron contents in the substantia nigra and striatum of PD mice.	[159]
siRNA/TMC-PEG-RVG (Particle size was in the range of 207 ± 2 nm with zeta potential of 9 ± 2.5 mV)	siRNA	AD	-	nAchR	<i>In vitro</i> and <i>in vivo</i> experiment showed excellent penetration into brain with low toxicity and higher serum stability.	[160]
AuNCs-RDP (Particle size was in the range of 10 ± 2.85 nm with zeta potential of -5.92 ± 3.16 mV)	Carboxyfluorescein	Neural cell imaging	Green synthetic route	RMT	<i>In vitro</i> and <i>in vivo</i> results suggested the effective internalization in the brain cells.	[161]

4.5. Dendrimers for brain drug delivery

Dendrimers are chemically synthesised polymeric particles with defined shapes (due to monodispersity). Dendrimers have been investigated for brain drug delivery. It has been reported, apolipoprotein A-I (ApoA-I) and NL4-peptide dual modified dendrimer NPs were efficient carriers for siRNA delivery to PC12 cells and efficiently penetrate through a bEnd.3 monolayer via LDLR [162]. KE *et al.* (2009) used PAMAM-PEG-Angiopep/DNA-NPs to deliver plasmid DNA across the BBB. The PAMAM was fifth generation with 128 surface primary amino groups. *In vitro* BBB model showed clathrin and caveolae-mediated endocytosis (also partly through macropinocytosis) of the nanocarriers containing Angiopep peptide [TFFYGGSRGKRNNFKTEEYC]. PAMAM-PEG-Angiopep dendrimers were loaded with pEGFP plasmid; and the NPs were administered intravenously to mice. Gene expression was observed in all four regions of the mouse brain for the PAMAM-PEG-Angiopep/DNA NPs, which was much higher than those for the PAMAM/DNA NPs [163]. In another study, low generation lysine dendrons (G0 and G1) conjugated with ApoE derived peptide (LRKLRKRLLR) were reported to cross the BBB efficiently with no cytotoxicity up to 400 μ M [164]. It should be noted that PAMAM/siRNA complexes appear to show significant cell toxicity even at low concentrations such as 20 μ g/mL [165]. As it would be expected, the cationic dendrimers show haemolytic activity. However, increasing the dendrimer generation decreases the haemolytic activity. For example, G2 dendrimers showed 100% haemolysis at 1 mg/mL concentration after 24 h incubation with RBCs, while G5 dendrimers showed no haemolysis (comparable to negative control) at the same concentration and incubation period [166]. Dynamic light scattering (DLS) studies showed that PAMAM/siRNA complexes had sizes in the range of 150-200 nm, while TEM results indicated a wider size distribution with majority in the range of 30-45 nm for G7 PAMAM/siRNA with N/P ratio of 10 [167].

4.6. Carbon Nanotubes

Carbon nanotubes (CNT) are cylindrical molecules that consist of rolled-up sheets of single-layer carbon atoms. Distinctive properties of CNT such as good electronic properties, excellent penetration into cell membrane, high loading capacity, pH-dependent unloading, greater surface area and ease of modification make them one of the suitable drug delivery system for the brain [168, 169]. CNT have been extensively investigated as a drug carrier to the brain in past few years. Functionalized CNT can potentially be used as a carrier for drugs that have poor permeability across the BBB and also can be used for diagnostic and for the treatment of brain disorders [170].

CNT can be synthesized electric arc discharge and laser ablation using vaporisation of graphite target [171] or by chemical vapour deposition [172]. CNT can be grouped into single wall carbon nanotubes (SWCNT) or multi wall carbon nanotubes (MWCNT) depending on the number of layers that constitute a CNT. CNT size ranges from 0.4nm to 100nm depending on the layers. CNT can be functionalized covalently or non-covalently [173].

Ren et al. (2012) developed PEGylated oxidized multi-walled carbon nanotubes (O-MWNTs) modified with angiopep-2 (O-MWNTs-PEG-ANG) to treat brain glioma. They reported the high uptake and accumulation of CNT in the desired area with excellent loading capacity. Angiopep-2 specifically binds to LDLR and promotes the internalization. Doxorubicin loaded CNT were found to have better anti-glioma effects than naked doxorubicin [174]. In another study, ANG functionalized radiolabelled CNT were employed to deliver drug across the BBB. *In vitro* experiments suggested higher penetration of ANG-CNT than chemically functionalized CNT. Enhanced localization of ANG-CNT was reported upon *in vivo* injection and 2% of the injected dose was accumulated in the brain within the first hour

post-injection [175, 176]. TAT (YGRKKRRQRRR) conjugated CNT were reported to have excellent BBB penetration and anticancer activity through increased ROS production [177].

4.7. Parameters affecting the BBB transport

4.7.1. Size, morphology and surface zeta potential

NPs in the range of 120-180 nm after crossing the BBB may be entrapped in the BL [178]. However, NPs with the size in the range of 16-24 nm are able to diffuse in the brain parenchyma [178]. These observations indicate that NPs should be less than 120 nm such as exosomes in order to diffuse in the brain parenchyma, otherwise they will remain trapped in the BL following crossing the BBB.

The morphology of NPs affects their bio-distribution and cellular uptake. NPs could be spherical, cubic, tubular or rod-like in shape [179, 180]. A majority of the particles reported for brain delivery are roughly spherical in shape. Zeta potential or surface charge of NPs is another factor that controls the diffusion across the BBB. It has been reported that a high (positive) zeta potential causes toxicity to the BBB [181, 182]. Rassu *et al.* (2017) reported that a positive surface charge on NPs ensures their mucoadhesion [183]. On the other hand, NP formulations have been reported for brain delivery with zeta potentials between -1 and -45 mV [184, 185, 186]. Different shapes of NPs are shown in [Figure 5](#).




Figure 5. Different morphologies and shapes of NPs used for brain drug delivery.

4.7.2. Critical micelle concentration (CMC)

CMC is the minimum concentration of a compound at which it forms micelles. CMC plays a major role in the stability of micelles/NPs due to excessive dilution in the blood, upon i.v. injection. If the concentration in systemic circulation drops below the CMC, then it releases the payload in the blood stream before getting to its target.

CMC can be determined by using set concentrations of a pyrene probe with serial dilution of copolymer solution [187, 188]. Ruan *et al.* (2018) used RAP12 peptide (a part of the receptor associated protein that binds to LRP1) and decorated PEG-poly(lactic acid) (PLA) micelles to deliver drug (paclitaxel) across the BBB [189]. Liu *et al.* (2009) reported CG₃R₆TAT (CGGGRRRRRRYGRKKRRQRRR), a self-assembled cationic antimicrobial peptide able to cross the BBB. They measured the CMC by using the pyrene as a probe and found to be 31.6 mg/L (10.1 μ M) in deionized water [187]. Micelles and PMNPs both can target the brain and cross the BBB. Efficacy and efficiency of crossing the BBB are dependent on targeting via the surface of the nanocarriers.

4.7.3. Protein corona

1
2
3 NPs, upon contact with biological fluids, are surrounded by a protein layer that is called
4 protein corona [190, 191, 192, 193]. The first layer of protein corona is bound tightly on the
5 surface (primary contact with NPs), which is referred as “hard” corona. Usually, another layer
6 is loosely bound on the first layer, which is referred as “soft” corona; and that consists of
7 serum proteins, mainly comprising albumin and its derivatives [194, 195, 196]. This surface
8 adsorption of protein can alter the physiological response [195]. The adsorption of proteins on
9 NPs mostly has undesirable effects such as prompt clearance from blood stream, compromised
10 targeting capacity [197] and toxicity [198, 199]. Proteins bound to a NP surface may rearrange
11 their structure and shape according to NP surface and environment, this is known as
12 “conformational change”. Conformational change accompanied with the modification of
13 secondary or tertiary protein structure. Proteins are supposed to interact with other
14 biomolecules to initiate biological responses, hence a small modification in protein structure
15 has huge impact on their pharmacological activities [200].

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 Several factors dictate the nature of adsorbed proteins. Particle size plays an important
35 role in protein adsorption. As NPs are bigger than proteins, NPs make proteins to adapt the
36 NPs’ surface. Smaller NPs has less interaction with proteins [201]. Surface charge of the NPs
37 affects the secondary structure of proteins. Huhn *et al.* (2014) reported that gold NPs with
38 different surface charge (positive [$+9.7 \pm 8.9$ mV] or negative [-39.8 ± 10.0 mV]), but similar
39 sizes adsorbed comparable amounts of HSA. Whereas, positively charged NPs showed higher
40 cellular uptake than negatively charged NPs. This change in the activity can be due to
41 conformation changes in protein structure due to surface charge [202]. Fleischer and Payne
42 (2014) observed that similar NPs with identical protein corona compositions bind to different
43 cellular receptors, suggesting that a difference in the structure of the adsorbed protein may be
44 responsible for the differences in cellular binding of the protein–NP complexes. These authors
45 also found that cationic polystyrene NPs showed improved cellular binding to monkey kidney

epithelial cells compared to negatively charged NPs in the presence of fetal bovine serum (FBS). It should be noted that in both cases, the NPs formed protein–NP complexes immediately following exposure to FBS [199].

Media composition affects the protein corona. Silica NPs in the presence of serum proteins showed less uptake compared to serum free media [203]. Gold NPs incubated with Dulbecco's Modified Eagle's Medium (DMEM) media for 48 h showed higher protein adsorption than Roswell Park Memorial Institute media (RPMI), but same amount after 1 hr incubation [204]. Protein concentration in media affects the protein corona. Silica NPs incubated with 3%, 20% and 80 % plasma exhibited different protein patterns. Changes in primary protein band was observed with increasing plasma concentration. Lower amounts of proteins were measured on silica NPs compared to sulfonated polystyrene (PSO₃) NPs with increased plasma concentrations [205]. Exposure time affects the protein corona. Protein corona forms immediately as soon as the NPs come into contact with human plasma. Tenzer *et al.* (2013) reported complex protein corona (formed of 300 proteins) just after 30 s [206]. In addition, temperature plays an important role in protein corona formation. Cu-NPs showed higher protein adsorption when incubated by increasing temperature from 15°C, 27°C, and 37°C to 42°C [207].

A decline (from 76% to 26%) in the cellular uptake of cRGD decorated NPs was reported by Su *et al.* (2018) in protein bound NPs compared to non-protein bound NPs. They found that even the targeting ability was not affected but cellular uptake was compromised [208]. Tf decorated NPs were reported to lose their targeting ability in the biological medium. Proteins in the medium are reported to shield the NPs and hence results in disappearance of targeting ability. However NPs can enter the cells but the targeting capacity is lost [209]. Aptamer functionalized AuNPs lost the targeting ability due to protein corona blocking after serum

exposure. Immune related proteins were found on the surface of aptamer that can induce immune reaction and clearance eventually [210].

4.7.4. Stability of NPs

The stability of NPs can be categorised into two, shelf stability and serum stability. NPs should be stable enough to retain their therapeutic effects for a specific time when stored or administered to the body. Oller-Salvia *et al.* (2016) tested the serum stability of peptide NPs in human serum. They found that switching from linear to monocyclic analogue didn't affect the permeability but showed 30-fold enhanced stability than linear peptide analogue [32]. In addition, upon switching disulphide to a lactam bridge in Miniap-4 shuttle peptide, they found 50% higher permeability with better resistance to proteases [32]. El-Marakby *et al.* (2017) assessed the serum stability of chitosan NPs in rat serum. They reported a sharp reduction in particle size (up to 62% of original size) prepared from the native chitosan, whereas modified chitosan showed slight increase in the size from 87.39 ± 1.56 nm to 122.33 ± 1.95 nm after 2 h incubation with the serum. After 24 h incubation no significant changes were noticed [211]. Oliveira *et al.* (2017), tested uncoated and poly allylamine hydrochloride (PAH)-coated PLGA-NPs in biological environments: BSA solution, mouse and human plasma. Both formulations were reported stable in BSA and mouse plasma on incubation, but surprisingly not stable in human plasma (formed aggregates greater than 1 μ m). They also studied protein corona in all solutions. In mouse plasma uncoated NPs showed protein concentration of 4.1 ± 2.6 μ g/mL, which was much greater than incubating these NPs in BSA solution. Surprisingly, in human plasma it was 2.5-fold higher (10.4 ± 3.0 μ g/mL) than mouse plasma. Similarly PAH-coated PLGA-NPs showed higher protein adsorption after incubation with human plasma than BSA solution and mouse plasma [212].

Uncoated chitosan NPs were to increase in size by storage at 25°C for 3 months in 10% glucose solution [213]. This alteration in size results in modified physicochemical, pharmacodynamic and pharmacokinetic properties of the PMNPs. Lyophilisation with cryoprotectants is reported to enhance the stability and to stop contents leaking from the NPs [214, 215, 216]. Cryoprotectants such as glucose, sucrose, mannitol and trehalose are most commonly used because of their low toxicity [214, 217].

5. Conclusion

Peptide based drug delivery systems have been studied extensively in the last two decades to overcome the BBB. Peptide based formulations come with its advantages (less toxicity, low alteration in the BBB integrity and specific targeting) and disadvantages (serum stability). Shuttle peptides, exosomes, liposomes, NPs and dendrimers decorated with peptides have shown much improved permeability across the BBB. Targeting and crossing the BBB is an ever expanding and challenging yet promising field. To design and develop a CNS drug that can target the BBB requires a detailed understanding of both the BBB at a molecular level and drug properties (pharmacokinetics and pharmacodynamics). Despite many advances in drug delivery systems, there is still an essential need for research aimed at attaining improved delivery systems with fewer limitations. Peptide based delivery systems along with pro and cons need further optimization and high specificity in brain targeting.

6. Future Direction

Despite extensive research in the use of peptides in nanoparticles for drug delivery to the brain, yet there is no clinical trial of them. Then, the next steps would be developing scalable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

and reproducible brain targeting nanoparticle delivery system using peptides as targeting ligands. Peptide based NPs provide the opportunity of formulating enzyme responsive or biodegradable delivery systems, which may offer less toxicity and immunogenicity, and improved efficacy. Peptide based nanoparticles should be able to deliver/encapsulate suitable amounts of drug to the brain; and these should protect the drug from enzymes in the blood.

7. Conflict of interest

The authors declare no conflict of interest.

8. References

1. Steward MM, Sridhar A, Meyer JS. Neural Regeneration. In: Heber-Katz E, Stocum DL, editors. New Perspectives in Regeneration. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 163-91.

2. Mahar M, Cavalli V. Intrinsic mechanisms of neuronal axon regeneration. *Nature Reviews Neuroscience*. 2018;19:323-37.
3. Chekani F, Bali V, Aparasu RR. Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. *Research in Social and Administrative Pharmacy*. 2016;12:604-13.
4. Josephs KA, Ahlskog JE, Parisi JE, Boeve BF, Crum BA, Giannini C, Petersen RC. Rapidly progressive neurodegenerative dementias. *Arch Neurol*. 2009;66:201-7. Epub 2009/02/11.
5. Organization WH. Neurological disorders affect millions globally: WHO report 2007 [cited 2018 06/08/2018]. Available from: <http://www.who.int/mediacentre/news/releases/2007/pr04/en/>.
6. Wenborn J, Hynes S, Moniz-Cook E, Mountain G, Poland F, King M, Omar R, Morris S, Vernooij-Dassen M, Challis D, Michie S, Russell I, Sackley C, Graff M, O'Keeffe A, Crellin N, Orrell M. Community occupational therapy for people with dementia and family carers (COTiD-UK) versus treatment as usual (Valuing Active Life in Dementia [VALID] programme): study protocol for a randomised controlled trial. *Trials*. 2016;17:65.
7. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. *Annals of Neurology*. 2017;81:479-84.
8. Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer Report, 2015. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer's Disease International (ADI). 2015.
9. Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. *Alzheimer's Research & Therapy*. 2016;8:39.
10. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L. Cost of disorders of the brain in Europe 2010. *European neuropsychopharmacology*. 2011;21:718-79.
11. Georgieff MK. Nutrition and the developing brain: nutrient priorities and measurement. *The American journal of clinical nutrition*. 2007;85:614S-20S.
12. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. *NeuroRx*. 2005;2:3-14.
13. Gururangan S, Friedman HS. Innovations in design and delivery of chemotherapy for brain tumors. *Neuroimaging Clinics of North America*. 2002;12:583-97.
14. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release*. 2016;235:34-47.
15. Rip J, Schenk G, De Boer A. Differential receptor-mediated drug targeting to the diseased brain. *Expert opinion on drug delivery*. 2009;6:227-37.
16. Treat LH, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K. Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. *Ultrasound in medicine & biology*. 2012;38:1716-25.
17. Pardridge WM. BBB-Genomics: creating new openings for brain-drug targeting. *Drug Discov Today*. 2001;6:381-3.
18. Potjewyd G, Moxon S, Wang T, Domingos M, Hooper NM. Tissue Engineering 3D Neurovascular Units: A Biomaterials and Bioprinting Perspective. *Trends in Biotechnology*. 2018;36:457-72.
19. Hawkins BT, Egleton RD. Pathophysiology of the blood-brain barrier: animal models and methods. *Current topics in developmental biology*. 2007;80:277-309.
20. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. *Nature Neuroscience*. 2011;14:1398-405.
21. Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. *Nature Neuroscience*. 2016;19:771.

22. Golden PL, Pollack GM. Blood–brain barrier efflux transport. *Journal of pharmaceutical sciences*. 2003;92:1739-53.
23. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. *Molecular medicine today*. 1996;2:106-13.
24. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. *Nature Reviews Neuroscience*. 2006;7:41-53.
25. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. *Journal of Pharmacological and Toxicological Methods*. 2000;44:235-49.
26. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. *NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics*. 2005;2:541-53.
27. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in *Advanced Drug Delivery Reviews* 23 (1997) 3–25.1. *Advanced Drug Delivery Reviews*. 2001;46:3-26.
28. Pardridge WM. Drug transport across the blood–brain barrier. *Journal of Cerebral Blood Flow & Metabolism*. 2012;32:1959-72.
29. Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. *Endocrine reviews*. 1986;7:314-30.
30. Kumar P, Wu H, McBride JL, Jung K-E, Hee Kim M, Davidson BL, Kyung Lee S, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. *Nature*. 2007;448:39.
31. Javed H, Menon SA, Al-Mansoori KM, Al-Wandi A, Majbour NK, Ardah MT, Varghese S, Vaikath NN, Haque ME, Azzouz M, El-Agnaf OM. Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2016;24:746-58. Epub 2016/01/26.
32. Oller - Salvia B, Sánchez - Navarro M, Ciudad S, Guíu M, Arranz - Gibert P, Garcia C, Gomis RR, Cecchelli R, García J, Giralte E. MiniAp - 4: A Venom - Inspired Peptidomimetic for Brain Delivery. *Angewandte Chemie*. 2016;128:582-5.
33. Neves V, Aires-da-Silva F, Morais M, Gano L, Ribeiro E, Pinto A, Aguiar S, Gaspar D, Fernandes C, Correia JDG, Castanho MARB. Novel Peptides Derived from Dengue Virus Capsid Protein Translocate Reversibly the Blood–Brain Barrier through a Receptor-Free Mechanism. *ACS Chemical Biology*. 2017;12:1257-68.
34. Lee J-H, Zhang A, You SS, Lieber CM. Spontaneous internalization of cell penetrating peptide-modified nanowires into primary neurons. *Nano letters*. 2016;16:1509-13.
35. Prades R, Oller-Salvia B, Schwarzmaier SM, Selva J, Moros M, Balbi M, Grazú V, de La Fuente JM, Egea G, Plesnila N, Teixidó M, Giralte E. Applying the Retro-Enantio Approach To Obtain a Peptide Capable of Overcoming the Blood–Brain Barrier. *Angewandte Chemie International Edition*. 2015;54:3967-72.
36. Zandl-Lang M, Fanaee-Danesh E, Sun Y, Albrecher NM, Gali CC, Čančar I, Kober A, Tam-Amersdorfer C, Stracke A, Storck SM, Saeed A, Stefulj J, Pietrzik CU, Wilson MR, Björkhem I, Panzenboeck U. Regulatory effects of simvastatin and apoJ on APP processing and amyloid- β clearance in blood-brain barrier endothelial cells. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. 2018;1863:40-60.
37. Li X, Peng J, Pang J, Wu Y, Huang X, Li Y, Zhou J, Gu L, Sun X, Chen L, Vitek MP, Jiang Y. Apolipoprotein E-Mimetic Peptide COG1410 Promotes Autophagy by Phosphorylating GSK-3 β in Early Brain Injury Following Experimental Subarachnoid Hemorrhage. *Frontiers in Neuroscience*. 2018;12.
38. Datta G, Chaddha M, Garber DW, Chung BH, Tytler EM, Dashti N, Bradley WA, Gianturco SH, Anantharamaiah GM. The Receptor Binding Domain of Apolipoprotein E, Linked to a Model Class A Amphipathic Helix, Enhances Internalization and Degradation of LDL by Fibroblasts. *Biochemistry*. 2000;39:213-20.

39. Wang D, El-Amouri SS, Dai M, Kuan C-Y, Hui DY, Brady RO, Pan D. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110:2999-3004.
40. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood–brain barrier. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104:7594-9.
41. Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X, Zhang Q. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. *Biomaterials*. 2012;33:5115-23.
42. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I Study of GRN1005 in Recurrent Malignant Glioma. *Clinical Cancer Research*. 2013;19:1567-76.
43. Tang S-C, Kumthekar P, Brenner AJ, Kesari S, Piccioni D, Anders CK, Carillo JA, Chalasani P, Kabos P, Puhalla SL, Garcia A, Tkaczuk K, Ahluwalia MS, Lakhani N, Ibrahim N. ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study. *Annals of Oncology*. 2016;27.
44. Li Y, Zheng X, Gong M, Zhang J. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. *Oncotarget*. 2016;7:79401-7.
45. Zou Z, Shen Q, Pang Y, Li X, Chen Y, Wang X, Luo X, Wu Z, Bao Z, Zhang J, Liang J, Kong L, Yan L, Xiong L, Zhu T, Yuan S, Wang M, Cai K, Yao Y, Wu J, Jiang Y, Liu H, Liu J, Zhou Y, Dong Q, Wang W, Zhu K, Li L, Lou Y, Wang H, Li Y, Lin H. The synthesized transporter K16APoE enabled the therapeutic HAYED peptide to cross the blood-brain barrier and remove excess iron and radicals in the brain, thus easing Alzheimer's disease. *Drug Delivery and Translational Research*. 2019;9:394-403.
46. Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K, Mizoguchi A. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. *Molecular Therapy*. 2018;26:1366-74.
47. Wu L-P, Ahmadvand D, Su J, Hall A, Tan X, Farhangrazi ZS, Moghimi SM. Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. *Nature Communications*. 2019;10:4635.
48. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier. *Journal of Controlled Release*. 2005;108:84-96.
49. Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, Navratilova E, Dhanasekaran M, Keyari CM, Yamamura HI, Porreca F, Hruby VJ, Polt R, Bilsky EJ. Antinociceptive Structure-Activity Studies with Enkephalin-Based Opioid Glycopeptides. *Journal of Pharmacology and Experimental Therapeutics*. 2004;311:290-7.
50. Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, Boeckers TM, Forni F, Zoli M. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. *Journal of Controlled Release*. 2014;174:195-201.
51. Tosi G, Bondioli L, Ruozi B, Badiali L, Severini GM, Biffi S, De Vita A, Bortot B, Dolcetta D, Forni F, Vandelli MA. NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. *Journal of Neural Transmission*. 2011;118:145-53.
52. Borros GS, RIVERO MFX, CASCANTE CA. Polypeptides for blood brain barrier transport. Google Patents; WO2014076655A1, 2014.
53. Demeule M, Régina A, Ché C, Poirier J, Nguyen T, Gabathuler R, Castaigne J-P, Béliveau R. Identification and Design of Peptides as a New Drug Delivery System for the Brain. *Journal of Pharmacology and Experimental Therapeutics*. 2008;324:1064-72.

54. Bertrand Y, Currie J-C, Demeule M, Régina A, Ché C, Abulrob A, Fatehi D, Sartelet H, Gabathuler R, Castaigne J-P, Stanimirovic D, Béliveau R. Transport characteristics of a novel peptide platform for CNS therapeutics. *Journal of Cellular and Molecular Medicine*. 2010;14:2827-39.
55. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse. *Science*. 1999;285:1569-72.
56. Arranz-Gibert P, Guixer B, Malakoutikhah M, Muttenthaler M, Guzmán F, Teixidó M, Giralte E. Lipid Bilayer Crossing—The Gate of Symmetry. Water-Soluble Phenylproline-Based Blood-Brain Barrier Shuttles. *Journal of the American Chemical Society*. 2015;137:7357-64.
57. Gregori M, Taylor M, Salvati E, Re F, Mancini S, Balducci C, Forloni G, Zambelli V, Sesana S, Michael M, Michail C, Tinker-Mill C, Kolosov O, Sherer M, Harris S, Fullwood NJ, Masserini M, Allsop D. Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's A β peptide. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2017;13:723-32.
58. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides. *Journal of Biological Chemistry*. 2003;278:31192-201.
59. Malcor J-D, Payrot N, David M, Faucon A, Abouzid K, Jacquot G, Floquet N, Debarbieux F, Rougon G, Martinez J, Khrestchatsky M, Vlieghe P, Lisowski V. Chemical Optimization of New Ligands of the Low-Density Lipoprotein Receptor as Potential Vectors for Central Nervous System Targeting. *Journal of Medicinal Chemistry*. 2012;55:2227-41.
60. Liu Y, Li J, Shao K, Huang R, Ye L, Lou J, Jiang C. A leptin derived 30-amino-acid peptide modified pegylated poly-l-lysine dendrigraft for brain targeted gene delivery. *Biomaterials*. 2010;31:5246-57.
61. Zhang C, Wan X, Zheng X, Shao X, Liu Q, Zhang Q, Qian Y. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. *Biomaterials*. 2014;35:456-65.
62. Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, Chen J, Pang Z, Wang Y, Jiang X, Yang VC, Wen L. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. *Biomaterials*. 2011;32:4943-50.
63. Zheng X, Pang X, Yang P, Wan X, Wei Y, Guo Q, Zhang Q, Jiang X. A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice. *Acta Biomaterialia*. 2017;49:388-401.
64. Yao H, Wang K, Wang Y, Wang S, Li J, Lou J, Ye L, Yan X, Lu W, Huang R. Enhanced blood-brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. *Biomaterials*. 2015;37:345-52.
65. Böckenhoff A, Cramer S, Wölte P, Knieling S, Wohlenberg C, Gieselmann V, Galla H-J, Matzner U. Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A. *The Journal of Neuroscience*. 2014;34:3122.
66. Georgieva JV, Brinkhuis RP, Stojanov K, Weijers CAGM, Zuilhof H, Rutjes FPJT, Hoekstra D, van Hest JCM, Zuhorn IS. Peptide - Mediated Blood-Brain Barrier Transport of Polymersomes. *Angewandte Chemie International Edition*. 2012;51:8339-42.
67. Zhang Y, Zhang W, Johnston AH, Newman TA, Pyykkö I, Zou J. Targeted delivery of Tet1 peptide functionalized polymersomes to the rat cochlear nerve. *International Journal of Nanomedicine*. 2012;7:1015-22.
68. Lee JH, Engler JA, Collawn JF, Moore BA. Receptor mediated uptake of peptides that bind the human transferrin receptor. *European Journal of Biochemistry*. 2001;268:2004-12.
69. Han L, Huang R, Liu S, Huang S, Jiang C. Peptide-Conjugated PAMAM for Targeted Doxorubicin Delivery to Transferrin Receptor Overexpressed Tumors. *Molecular Pharmaceutics*. 2010;7:2156-65.
70. Xie Y, Killinger B, Moszczynska A, Merkel O. Targeted Delivery of siRNA to Transferrin Receptor Overexpressing Tumor Cells via Peptide Modified Polyethylenimine. *Molecules*. 2016;21:1334.
71. Wang Z, Zhao Y, Jiang Y, Lv W, Wu L, Wang B, Lv L, Xu Q, Xin H. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. *Scientific Reports*. 2015;5:12651.
72. Lledó EG, Turà MT, Cosano RP. Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs. Google Patents; US20150044140A1, 2016.

73. Arranz-Gibert P, Ciudad S, Seco J, García J, Giralt E, Teixidó M. Immunosilencing peptides by stereochemical inversion and sequence reversal: retro-D-peptides. *Scientific Reports*. 2018;8:6446.
74. Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, Selva J, Egea G, Lopez-Iglesias C, Teixido M, Kogan MJ, Giralt E. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. *Biomaterials*. 2012;33:7194-205. Epub 2012/07/17.
75. Díaz-Perlas C, Oller-Salvia B, Sánchez-Navarro M, Teixidó M, Giralt E. Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport. *Chemical science*. 2018;9:8409-15.
76. Teixidó M, Zurita E, Mendieta L, Oller - Salvia B, Prades R, Tarragó T, Giralt E. Dual system for the central nervous system targeting and blood - brain barrier transport of a selective prolyl oligopeptidase inhibitor. *Peptide Science*. 2013;100:662-74.
77. Lindqvist A, Rip J, Gaillard PJ, Björkman S, Hammarlund-Udenaes M. Enhanced Brain Delivery of the Opioid Peptide DAMGO in Glutathione PEGylated Liposomes: A Microdialysis Study. *Molecular Pharmaceutics*. 2013;10:1533-41.
78. Rotman M, Welling MM, Bunschoten A, de Backer ME, Rip J, Nabuurs RJA, Gaillard PJ, van Buchem MA, van der Maarel SM, van der Weerd L. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. *Journal of Controlled Release*. 2015;203:40-50.
79. Gaillard PJ, Appeldoorn CCM, Rip J, Dorland R, van der Pol SMA, Kooij G, de Vries HE, Reijerkerk A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. *Journal of Controlled Release*. 2012;164:364-9.
80. Wei X, Zhan C, Shen Q, Fu W, Xie C, Gao J, Peng C, Zheng P, Lu W. A D - Peptide Ligand of Nicotine Acetylcholine Receptors for Brain - Targeted Drug Delivery. *Angewandte Chemie International Edition*. 2015;54:3023-7.
81. Zhan C, Li B, Hu L, Wei X, Feng L, Fu W, Lu W. Micelle - Based Brain - Targeted Drug Delivery Enabled by a Nicotine Acetylcholine Receptor Ligand. *Angewandte Chemie International Edition*. 2011;50:5482-5.
82. Staquicini FI, Ozawa MG, Moya CA, Driessen WHP, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, 2nd, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Höök M, Gelovani JG, Sidman RL, Cavenee WK, Pasqualini R, Arap W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. *The Journal of Clinical Investigation*. 2011;121:161-73.
83. Urich E, Schmucki R, Ruderisch N, Kitas E, Certa U, Jacobsen H, Schweitzer C, Bergadano A, Ebeling M, Loetscher H, Freskgård P-O. Cargo Delivery into the Brain by in vivo identified Transport Peptides. *Scientific Reports*. 2015;5:14104.
84. Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She Z-G, Kotamraju VR, Ranscht B, Krajewski S, Teesalu T, Bhatia S, Sailor MJ, Ruoslahti E. A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. *Nature Communications*. 2016;7:11980.
85. Zhang X, He T, Chai Z, Samulski RJ, Li C. Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. *Biomaterials*. 2018;176:71-83.
86. Prokop A, Davidson JM. Nanovehicular Intracellular Delivery Systems. *Journal of pharmaceutical sciences*. 2008;97:3518-90.
87. Nunzio D, Adriana T, Valentino L, Angela L, Giuseppe T. Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain. *Current Topics in Medicinal Chemistry*. 2009;9:182-96.
88. Arnold AE, Czipiel P, Shoichet M. Engineered polymeric nanoparticles to guide the cellular internalization and trafficking of small interfering ribonucleic acids. *Journal of Controlled Release*. 2017;259:3-15.
89. Dong X. Current Strategies for Brain Drug Delivery. *Theranostics*. 2018;8:1481-93.

90. Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. *Journal of Controlled Release*. 1995;36:49-61.
91. Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B, Singh J. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection. *Journal of Controlled Release*. 2013;167:1-10.
92. Urbiola K, Blanco-Fernández L, Ogris M, Rödl W, Wagner E, Tros de Ilarduya C. Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors. *Journal of Personalized Medicine*. 2018;8:4.
93. Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, Marin O, Vandelli MA, Forni F, Scarpa M, Tomanin R, Tosi G. Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders. *PLoS One*. 2016;11:e0156452.
94. Luo Z, Jin K, Pang Q, Shen S, Yan Z, Jiang T, Zhu X, Yu L, Pang Z, Jiang X. On-Demand Drug Release from Dual-Targeting Small Nanoparticles Triggered by High-Intensity Focused Ultrasound Enhanced Glioblastoma-Targeting Therapy. *ACS Applied Materials & Interfaces*. 2017;9:31612-25.
95. Lu F, Pang Z, Zhao J, Jin K, Li H, Pang Q, Zhang L, Pang Z. Angiopep-2-conjugated poly(ethylene glycol)-co- poly(epsilon-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. *Int J Nanomedicine*. 2017;12:2117-27. Epub 2017/03/31.
96. Di Mauro PP, Cascante A, Brugada Vilà P, Gómez-Vallejo V, Llop J, Borrós S. Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma. *International Journal of Pharmaceutics*. 2018;553:169-85.
97. Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, Ramakrishnan S, Poduslo JF, Kandimalla KK. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2019;16:258-66.
98. Ghorbani M, Bigdeli B, Jalili-baleh L, Baharifar H, Akrami M, Dehghani S, Goliaei B, Amani A, Lotfabad A, Rashedi H, Haririan I, Alam NR, Hamedani MP, Khoobi M. Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of gold-iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. *Eur J Pharm Sci*. 2018;114:175-88.
99. Nosrati H, Tarantash M, Bochani S, Charmi J, Bagheri Z, Fridoni M, Abdollahifar M-A, Davaran S, Danafar H, Kheiri Manjili H. Glutathione (GSH) Peptide Conjugated Magnetic Nanoparticles As Blood-Brain Barrier Shuttle for MRI-Monitored Brain Delivery of Paclitaxel. *ACS Biomaterials Science & Engineering*. 2019;5:1677-85.
100. Wang S, Zhang B, Su L, Nie W, Han D, Han G, Zhang H, Chong C, Tan J. Subcellular distributions of iron oxide nanoparticles in rat brains affected by different surface modifications. *Journal of Biomedical Materials Research Part A*. 2019;107:1988-98.
101. Albertini B, Mathieu V, Iraci N, Van Woensel M, Schoubben A, Donnadio A, Greco SML, Ricci M, Temperini A, Blasi P, Wauthoz N. Tumor Targeting by Peptide-Decorated Gold Nanoparticles. *Molecular Pharmaceutics*. 2019;16:2430-44.
102. Yang L, Qian W, Scott P, Shao X. Towards the development of brain-penetrating gold nanoparticle-transactivator of transcription (TAT) peptide conjugates. *Journal of Nuclear Medicine*. 2018;59:1034-.
103. Zhao L, Li Y, Zhu J, Sun N, Song N, Xing Y, Huang H, Zhao J. Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy. *Journal of Nanobiotechnology*. 2019;17:30.
104. Ivask A, Pilkington EH, Blin T, Käkinen A, Vija H, Visnapuu M, Quinn JF, Whittaker MR, Qiao R, Davis TP, Ke PC, Voelcker NH. Uptake and transcytosis of functionalized superparamagnetic iron oxide nanoparticles in an in vitro blood brain barrier model. *Biomaterials Science*. 2018;6:314-23.

105. Vinzant N, Scholl JL, Wu C-M, Kindle T, Koodali R, Forster GL. Iron Oxide Nanoparticle Delivery of Peptides to the Brain: Reversal of Anxiety during Drug Withdrawal. *Frontiers in neuroscience*. 2017;11:608-.
106. Ghadiri M, Vasheghani - Farahani E, Atyabi F, Kobarfard F, Mohamadyar - Toupkanlou F, Hosseinkhani H. Transferrin - conjugated magnetic dextran - spermine nanoparticles for targeted drug transport across blood - brain barrier. *Journal of Biomedical Materials Research Part A*. 2017;105:2851-64.
107. Kang J, Joo J, Kwon EJ, Skalak M, Hussain S, She Z-G, Ruoslahti E, Bhatia SN, Sailor MJ. Self-Sealing Porous Silicon-Calcium Silicate Core-Shell Nanoparticles for Targeted siRNA Delivery to the Injured Brain. *Advanced Materials*. 2016;28:7962-9.
108. Lee C, Hwang HS, Lee S, Kim B, Kim JO, Oh KT, Lee ES, Choi H-G, Youn YS. Rabies Virus-Inspired Silica-Coated Gold Nanorods as a Photothermal Therapeutic Platform for Treating Brain Tumors. *Advanced Materials*. 2017;29:1605563.
109. Etame AB, Smith CA, Chan WCW, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2011;7:992-1000.
110. Hanada S, Fujioka K, Inoue Y, Kanaya F, Manome Y, Yamamoto K. Cell-Based in Vitro Blood-Brain Barrier Model Can Rapidly Evaluate Nanoparticles' Brain Permeability in Association with Particle Size and Surface Modification. *International Journal of Molecular Sciences*. 2014;15:1812.
111. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. *Colloids and Surfaces B: Biointerfaces*. 2008;66:274-80.
112. Takeuchi I, Nobata S, Oiri N, Tomoda K, Makino K. Biodistribution and excretion of colloidal gold nanoparticles after intravenous injection: Effects of particle size. *Bio-Medical Materials and Engineering*. 2017;28:315-23.
113. Ruff J, Hüwel S, Kogan MJ, Simon U, Galla H-J. The effects of gold nanoparticles functionalized with β -amyloid specific peptides on an in vitro model of blood-brain barrier. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2017;13:1645-52.
114. Shilo M, Sharon A, Baranes K, Motiei M, Lellouche J-PM, Popovtzer R. The effect of nanoparticle size on the probability to cross the blood - brain barrier: an in-vitro endothelial cell model.(Research)(Report). 2015;13:19.
115. Kang MH, Lee SJ, Park JY, Park JK. Carbon-coated copper nanoparticles: Characterization and fabrication via ultrasonic irradiation. *Journal of Alloys and Compounds*. 2018;735:2162-6.
116. Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: Synthesis, preparation and in vivo evaluation. *Journal of Controlled Release*. 2012;159:429-34.
117. Niu J, Wang A, Ke Z, Zheng Z. Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating. *Journal of Drug Targeting*. 2014;22:712-23.
118. Lopalco A, Ali H, Denora N, Rytting E. Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. *International Journal of Nanomedicine*. 2015;10:1985-96.
119. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, Batrakova EV. Exosomes as drug delivery vehicles for Parkinson's disease therapy. *Journal of Controlled Release*. 2015;207:18-30.
120. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. *Nature Reviews Immunology*. 2014;14:195.
121. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature Cell Biology*. 2007;9:654.

122. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Curry Jr WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nature Cell Biology*. 2008;10:1470.
123. Das CK, Jena BC, Banerjee I, das S, Parekh A, Bhutia SK, Mandal M. Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers. *Mol Pharm*. 2018. Epub 2018/12/05.
124. Yamashita T, Takahashi Y, Takakura Y. Possibility of Exosome-Based Therapeutics and Challenges in Production of Exosomes Eligible for Therapeutic Application. *Biological & pharmaceutical bulletin*. 2018;41:835-42. Epub 2018/06/05.
125. Barile L, Vassalli G. Exosomes: Therapy delivery tools and biomarkers of diseases. *Pharmacology & therapeutics*. 2017;174:63-78. Epub 2017/02/17.
126. Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. *Acta Pharm Sin B*. 2016;6:287-96. Epub 2016/03/08.
127. Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, Pereira de Almeida L. Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. *Journal of controlled release : official journal of the Controlled Release Society*. 2017;262:247-58. Epub 2017/07/09.
128. Druzhkova TA, Yakovlev AA. Exosome Drug Delivery through the Blood–Brain Barrier: Experimental Approaches and Potential Applications. *Neurochemical Journal*. 2018;12:195-204.
129. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. *Int J Nanomedicine*. 2012;7:1525-41. Epub 2012/05/24.
130. Lu M, Xing H, Xun Z, Yang T, Zhao X, Cai C, Wang D, Ding P. Functionalized extracellular vesicles as advanced therapeutic nanodelivery systems. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2018;121:34-46. Epub 2018/05/08.
131. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplateforms for drug delivery. *Acta pharmacologica Sinica*. 2017;38:754-63. Epub 2017/04/11.
132. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhani S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nature Biotechnology*. 2011;29:341.
133. Tian T, Zhang H-X, He C-P, Fan S, Zhu Y-L, Qi C, Huang N-P, Xiao Z-D, Lu Z-H, Tannous BA, Gao J. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. *Biomaterials*. 2018;150:137-49.
134. Long Q, Upadhyay D, Hattiangady B, Kim D-K, An SY, Shuai B, Prockop DJ, Shetty AK. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. *Proceedings of the National Academy of Sciences*. 2017;114:E3536.
135. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, Miller D, Zhang H-G. Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-inflammatory Drugs From the Nasal Region to the Brain. *Molecular Therapy*. 2011;19:1769-79.
136. Pusic AD, Pusic KM, Clayton BL, Kraig RP. IFN γ -stimulated dendritic cell exosomes as a potential therapeutic for remyelination. *Journal of neuroimmunology*. 2014;266:12-23. Epub 2013/11/28.
137. Jia G, Han Y, An Y, Ding Y, He C, Wang X, Tang Q. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. *Biomaterials*. 2018;178:302-16.
138. Iraci N, Gaude E, Leonardi T, Costa ASH, Cossetti C, Peruzzotti-Jametti L, Bernstock JD, Saini HK, Gelati M, Vescovi AL, Bastos C, Faria N, Occhipinti LG, Enright AJ, Frezza C, Pluchino S. Extracellular vesicles are independent metabolic units with asparaginase activity. *Nature chemical biology*. 2017;13:951-5. Epub 2017/07/04.

139. Cooper JM, Wiklander PBO, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, Schapira AHV, Simons JP, El-Andaloussi S, Alvarez-Erviti L. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. *Movement Disorders*. 2014;29:1476-85.
140. Qu M, Lin Q, Huang L, Fu Y, Wang L, He S, Fu Y, Yang S, Zhang Z, Zhang L, Sun X. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease. *Journal of Controlled Release*. 2018;287:156-66.
141. Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. *Oncotarget*. 2015;6:37043-53.
142. Liu Y, Li D, Liu Z, Zhou Y, Chu D, Li X, Jiang X, Hou D, Chen X, Chen Y, Yang Z, Jin L, Jiang W, Tian C, Zhou G, Zen K, Zhang J, Zhang Y, Li J, Zhang C-Y. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. *Scientific Reports*. 2015;5:17543.
143. Wu T, Yu M, Zhang L, Chen X, Pei Z. I02 Systemic injection of exosomal sirna significantly reduced huntingtin expression in transgenic mice of huntington's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2018;89:A88-A9.
144. Singh RP, Gangadharappa HV, Mruthunjaya K. Phospholipids: Unique carriers for drug delivery systems. *Journal of Drug Delivery Science and Technology*. 2017;39:166-79.
145. Pulford B, Reim N, Bell A, Veatch J, Forster G, Bender H, Meyerett C, Hafeman S, Michel B, Johnson T, Wyckoff AC, Miele G, Julius C, Kranich J, Schenkel A, Dow S, Zabel MD. Liposome-siRNA-Peptide Complexes Cross the Blood-Brain Barrier and Significantly Decrease PrP(C) on Neuronal Cells and PrP(RES) in Infected Cell Cultures. *PLoS One*. 2010;5:e11085.
146. Bender HR, Kane S, Zabel MD. Delivery of therapeutic siRNA to the CNS using cationic and anionic liposomes. *Journal of visualized experiments: JoVE*. 2016.
147. Grinberg S, Linder C, Kolot V, Waner T, Wiesman Z, Shaubi E, Heldman E. Novel Cationic Amphiphilic Derivatives from Vernonia Oil: Synthesis and Self-Aggregation into Bilayer Vesicles, Nanoparticles, and DNA Complexants. *Langmuir*. 2005;21:7638-45.
148. Popov M, Abu Hammad I, Bachar T, Grinberg S, Linder C, Stepensky D, Heldman E. Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes. *European Journal of Pharmaceutics and Biopharmaceutics*. 2013;85:381-9. Epub 2013/06/25.
149. Conceição M, Mendonça L, Nóbrega C, Gomes C, Costa P, Hirai H, Moreira JN, Lima MC, Manjunath N, Pereira de Almeida L. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. *Biomaterials*. 2016;82:124-37.
150. Ana Rute N, Joana Fontes Q, Babette W, Ignacio AR, Pierre-Olivier C, Salette R. Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E. *Nanotechnology*. 2015;26:495103.
151. Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, Yang VC, Huang Y. Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. *ACS Nano*. 2016;10:9999-10012.
152. Xia H, Gao X, Gu G, Liu Z, Hu Q, Tu Y, Song Q, Yao L, Pang Z, Jiang X, Chen J, Chen H. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. *International Journal of Pharmaceutics*. 2012;436:840-50.
153. Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X. Angiopep-conjugated poly(ethylene glycol)-co-poly(ϵ -caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. *Biomaterials*. 2011;32:4293-305.
154. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC, Ling E-A, Moomchala S, Yang Y-Y. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. *Biomaterials*. 2008;29:1509-17.
155. Hua H, Zhang X, Mu H, Meng Q, Jiang Y, Wang Y, Lu X, Wang A, Liu S, Zhang Y, Wan Z, Sun K. RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy. *International Journal of Pharmaceutics*. 2018;543:179-89.

156. Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H, Shiraishi S, Takashima Y, Suzuki T, Seta Y. Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide. *International Journal of Pharmaceutics*. 2017;530:195-200.
157. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. *Journal of Controlled Release*. 2007;122:1-9.
158. Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozi B, Forni F, Vandelli MA. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. *Nanomedicine*. 2011;6:423-36.
159. You L, Wang J, Liu T, Zhang Y, Han X, Wang T, Guo S, Dong T, Xu J, Anderson GJ, Liu Q, Chang Y-Z, Lou X, Nie G. Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice. *ACS Nano*. 2018;12:4123-39.
160. Gao Y, Wang Z-Y, Zhang J, Zhang Y, Huo H, Wang T, Jiang T, Wang S. RVG-Peptide-Linked Trimethylated Chitosan for Delivery of siRNA to the Brain. *Biomacromolecules*. 2014;15:1010-8.
161. Zhang E, Fu A. A new strategy for specific imaging of neural cells based on peptide-conjugated gold nanoclusters. *International journal of nanomedicine*. 2015;10:2115.
162. Zhang C, Gu Z, Shen L, Liu X, Lin H. A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering siRNA to Neurons for Alzheimer's Disease Treatment. *Curr Pharm Biotechnol*. 2017;18:1124-31. Epub 2018/02/28.
163. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. *Biomaterials*. 2009;30:6976-85.
164. Al-Azzawi S, Masheta D, Guildford A, Phillips G, Santin M. Designing and Characterization of a Novel Delivery System for Improved Cellular Uptake by Brain Using Dendronised Apo-E-Derived Peptide. *Frontiers in Bioengineering and Biotechnology*. 2019;7:49. Epub 2019/04/12.
165. Kang H, DeLong R, Fisher MH, Juliano RL. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. *Pharm Res*. 2005;22:2099-106. Epub 2005/09/27.
166. Chen HT, Neerman MF, Parrish AR, Simanek EE. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. *J Am Chem Soc*. 2004;126:10044-8. Epub 2004/08/12.
167. Perez AP, Romero EL, Morilla MJ. Ethylenediamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. *Int J Pharm*. 2009;380:189-200. Epub 2009/07/07.
168. Kubota Y, Sohn J, Hatada S, Schurr M, Straehle J, Gour A, Neujahr R, Miki T, Mikula S, Kawaguchi Y. A carbon nanotube tape for serial-section electron microscopy of brain ultrastructure. *Nature Communications*. 2018;9:437.
169. Herlem G, Picaud F, Girardet C, Micheau O. Chapter 16 - Carbon Nanotubes: Synthesis, Characterization, and Applications in Drug-Delivery Systems. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S, editors. *Nanocarriers for Drug Delivery*: Elsevier; 2019. p. 469-529.
170. Costa PM, Wang JT-W, Morfin J-F, Khanum T, To W, Sosabowski J, Tóth E, Al-Jamal KT. Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands. *Nanotheranostics*. 2018;2:168-83.
171. Journet C, Maser WK, Bernier P, Loiseau A, de la Chapelle ML, Lefrant S, Deniard P, Lee R, Fischer JE. Large-scale production of single-walled carbon nanotubes by the electric-arc technique. *Nature*. 1997;388:756-8.
172. Huang ZP, Xu JW, Ren ZF, Wang JH, Siegal MP, Provencio PN. Growth of highly oriented carbon nanotubes by plasma-enhanced hot filament chemical vapor deposition. *Applied Physics Letters*. 1998;73:3845-7.
173. Zhang W, Zhang Z, Zhang Y. The application of carbon nanotubes in target drug delivery systems for cancer therapies. *Nanoscale research letters*. 2011;6:555.

174. Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z, Qian Y, Sun X, Jiang X. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. *Biomaterials*. 2012;33:3324-33.
175. Kafa H, Wang JT-W, Rubio N, Klippstein R, Costa PM, Hassan HAFM, Sosabowski JK, Bansal SS, Preston JE, Abbott NJ, Al-Jamal KT. Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood–brain barrier in vitro and in vivo. *Journal of Controlled Release*. 2016;225:217-29.
176. Kafa H, Wang JT-W, Rubio N, Venner K, Anderson G, Pach E, Ballesteros B, Preston JE, Abbott NJ, Al-Jamal KT. The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo. *Biomaterials*. 2015;53:437-52.
177. You Y, Wang N, He L, Shi C, Zhang D, Liu Y, Luo L, Chen T. Designing dual-functionalized carbon nanotubes with high blood–brain-barrier permeability for precise orthotopic glioma therapy. *Dalton Transactions*. 2019;48:1569-73.
178. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. *AJNR American journal of neuroradiology*. 1999;20:217-22. Epub 1999/03/27.
179. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. *Journal of Controlled Release*. 2010;141:320-7.
180. Jucker BM, Alsaïd H, Rambo M, Lenhard SC, Hoang B, Xie F, Groseclose MR, Castellino S, Damian V, Bowers G, Gupta M. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat. *Journal of Controlled Release*. 2017;268:102-12.
181. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability. *Journal of Drug Targeting*. 2004;12:635-41.
182. Torchilin VP. Multifunctional nanocarriers. *Advanced Drug Delivery Reviews*. 2006;58:1532-55.
183. Rassu G, Soddu E, Posadino AM, Pintus G, Sarmento B, Giunchedi P, Gavini E. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy. *Colloids and Surfaces B: Biointerfaces*. 2017;152:296-301.
184. Johnsen KB, Burkhart A, Melander F, Kempen PJ, Vejlebo JB, Siupka P, Nielsen MS, Andresen TL, Moos T. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. *Scientific Reports*. 2017;7:10396.
185. Bramini M, Ye D, Hallerbach A, Nic Raghnaill M, Salvati A, Aberg C, Dawson KA. Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. *ACS Nano*. 2014;8:4304-12. Epub 2014/04/30.
186. Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110:8662-7. Epub 2013/05/06.
187. Liu L, Xu K, Wang H, Jeremy Tan PK, Fan W, Venkatraman SS, Li L, Yang Y-Y. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. *Nature Nanotechnology*. 2009;4:457.
188. Shaki H, Ganji F, Kempen PJ, Dolatshahi-Pirouz A, Vasheghani-Farahani E. Self-assembled amphiphilic-dextran nanomicelles for delivery of rapamycin. *J Drug Deliv Sci Technol*. 2018;44:333-41.
189. Ruan H, Chai Z, Shen Q, Chen X, Su B, Xie C, Zhan C, Yao S, Wang H, Zhang M, Ying M, Lu W. A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery. *Journal of Controlled Release*. 2018;279:306-15.
190. Oh JY, Kim HS, Palanikumar L, Go EM, Jana B, Park SA, Kim HY, Kim K, Seo JK, Kwak SK, Kim C, Kang S, Ryu J-H. Cloaking nanoparticles with protein corona shield for targeted drug delivery. *Nature Communications*. 2018;9:4548.

191. Gorshkov V, Bubis JA, Solovyeva EM, Gorshkov MV, Kjeldsen F. Protein corona formed on silver nanoparticles in blood plasma is highly selective and resistant to physicochemical changes of the solution. *Environmental Science: Nano*. 2019;6:1089-98.
192. García-Álvarez R, Hadjidemetriou M, Sánchez-Iglesias A, Liz-Marzán LM, Kostarelos K. In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape. *Nanoscale*. 2018;10:1256-64.
193. Nierenberg D, Khaled AR, Flores O. Formation of a protein corona influences the biological identity of nanomaterials. *Reports of Practical Oncology & Radiotherapy*. 2018;23:300-8.
194. Phogat N, Kohl M, Uddin I, Jahan A. Chapter 11 - Interaction of Nanoparticles With Biomolecules, Protein, Enzymes, and Its Applications. In: Deigner H-P, Kohl M, editors. *Precision Medicine*: Academic Press; 2018. p. 253-76.
195. Mosquera J, García I, Henriksen-Lacey M, González-Rubio G, Liz-Marzán LM. Reducing Protein Corona Formation and Enhancing Colloidal Stability of Gold Nanoparticles by Capping with Silica Monolayers. *Chemistry of Materials*. 2018;31:57-61.
196. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell "sees" in bionanoscience. *Journal of the American Chemical Society*. 2010;132:5761-8.
197. Gräfe C, Weidner A, Lühe Mvd, Bergemann C, Schacher FH, Clement JH, Dutz S. Intentional formation of a protein corona on nanoparticles: Serum concentration affects protein corona mass, surface charge, and nanoparticle-cell interaction. *The International Journal of Biochemistry & Cell Biology*. 2016;75:196-202.
198. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. *Science*. 2013;339:971-5.
199. Fleischer CC, Payne CK. Nanoparticle-cell interactions: molecular structure of the protein corona and cellular outcomes. *Acc Chem Res*. 2014;47:2651-9. Epub 2014/07/11.
200. Lynch I, Dawson KA. Protein-nanoparticle interactions. *Nano today*. 2008;3:40-7.
201. Asuri P, Bale SS, Pangule RC, Shah DA, Kane RS, Dordick JS. Structure, function, and stability of enzymes covalently attached to single-walled carbon nanotubes. *Langmuir*. 2007;23:12318-21.
202. Hühn D, Kantner K, Geidel C, Brandholt S, De Cock I, Soenen SJH, Rivera_Gil P, Montenegro J-M, Braeckmans K, Müllen K, Nienhaus GU, Klapper M, Parak WJ. Polymer-Coated Nanoparticles Interacting with Proteins and Cells: Focusing on the Sign of the Net Charge. *ACS Nano*. 2013;7:3253-63.
203. Lesniak A, Fenaroli F, Monopoli MP, Åberg C, Dawson KA, Salvati A. Effects of the Presence or Absence of a Protein Corona on Silica Nanoparticle Uptake and Impact on Cells. *ACS Nano*. 2012;6:5845-57.
204. Maiorano G, Sabella S, Sorce B, Brunetti V, Malvindi MA, Cingolani R, Pompa PP. Effects of Cell Culture Media on the Dynamic Formation of Protein-Nanoparticle Complexes and Influence on the Cellular Response. *ACS Nano*. 2010;4:7481-91.
205. Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Baldelli Bombelli F, Dawson KA. Physical-Chemical Aspects of Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles. *Journal of the American Chemical Society*. 2011;133:2525-34.
206. Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, Schlenk F, Fischer D, Kiouptsi K, Reinhardt C. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. *Nature Nanotechnology*. 2013;8:772.
207. Bhogale A, Patel N, Mariam J, Dongre PM, Miotello A, Kothari DC. Comprehensive studies on the interaction of copper nanoparticles with bovine serum albumin using various spectroscopies. *Colloids and Surfaces B: Biointerfaces*. 2014;113:276-84.
208. Su G, Jiang H, Xu B, Yu Y, Chen X. Effects of Protein Corona on Active and Passive Targeting of Cyclic RGD Peptide-Functionalized PEGylation Nanoparticles. *Molecular Pharmaceutics*. 2018;15:5019-30.

209. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, Kelly PM, Åberg C, Mahon E, Dawson KA. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. *Nature Nanotechnology*. 2013;8:137.
210. Ding D, Zhang Y, Sykes EA, Chen L, Chen Z, Tan W. The influence of physiological environment on the targeting effect of aptamer-guided gold nanoparticles. *Nano Research*. 2019;12:129-35.
211. El-Marakby EM, Hathout RM, Taha I, Mansour S, Mortada ND. A novel serum-stable liver targeted cytotoxic system using valerate-conjugated chitosan nanoparticles surface decorated with glycyrrhizin. *International Journal of Pharmaceutics*. 2017;525:123-38.
212. Oliveira CL, Veiga F, Varela C, Roleira F, Tavares E, Silveira I, Ribeiro AJ. Characterization of polymeric nanoparticles for intravenous delivery: Focus on stability. *Colloids and Surfaces B: Biointerfaces*. 2017;150:326-33.
213. Almalik A, Alradwan I, Kalam MA, Alshamsan A. Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating. *Saudi Pharmaceutical Journal*. 2017;25:861-7.
214. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. *Advanced Drug Delivery Reviews*. 2006;58:1688-713.
215. Gokce Y, Cengiz B, Yildiz N, Calimli A, Aktas Z. Ultrasonication of chitosan nanoparticle suspension: Influence on particle size. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. 2014;462:75-81.
216. Rampino A, Borgogna M, Blasi P, Bellich B, Cesàro A. Chitosan nanoparticles: Preparation, size evolution and stability. *International Journal of Pharmaceutics*. 2013;455:219-28.
217. Cesur H, Rubinstein I, Pai A, Önyüksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2009;5:178-83.